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Abstract 
Discovery of Host-Microbiota Interactions 
Connor Edwin Rosen 
2021 
 
The microbiota, comprising the trillions of microorganisms that colonize barrier 
tissues, exert profound effects on host health and disease. Microbial effects on host 
physiology have been illuminated by a wealth of sequencing-based approaches that 
enumerate bacterial species, strains, genes, and products (collectively, “multi-omics” 
approaches) at different tissue sites and in different human populations. Microbes may 
influence local physiology at their site of residence, as well as having systemic effects 
including perturbation of organism-wide metabolism, with wide-ranging consequences. 
The molecular mechanisms by which microbes mediate both local and systemic effects, 
however, remain mostly unclear. This is in part due to technological limitations in 
profiling microbes at the scales necessary to characterize the thousands of unique strains 
and species that comprise the collective human microbiota. The identification of specific 
host pathways engaged or modulated by particular microbes will provide insight into how 
the microbiota impacts host physiology, and suggest nodes of intervention for the 
amelioration of microbiota-mediated disorders. In this thesis, I will describe a new 
technological approach to profile direct microbial interactions with the host and how 




In Chapter 1, I present a brief introduction to the microbiota, with a particular 
focus of the intestinal microbiota, along with an introduction to the importance of 
“functional profiling” to describe and classify the microbiota. The intestine is the most 
densely populated organ by microbial cells, and includes a diverse range of 
microenvironments that support a large diversity of microbes. Functional profiling may 
support traditional multi-omics approaches to identify critical microbes or pathways in 
host-microbe connection. In Chapter 2, I discuss selective pressures facing the intestinal 
microbiota, to contextualize the functional profiling program of interest, an effort to 
discovery direct cellular host-microbe interactions. In Chapter 3, I introduce yeast surface 
display methodology and the design and creation of a library of human exoproteins that is 
useful for interrogating binding partners of host exoproteins, validated and highlighted by 
the discovery of the targets of human autoantibodies in autoimmune diseases. In Chapter 
4, I present BASEHIT, a new technique for screening microbial cells using yeast surface 
display libraries. I use BASEHIT to characterize the host binding patterns of hundreds of 
microbes and describe the nature of interactions discovered as well as several particular 
interactions of interest. In Chapters 5, I illustrate how BASEHIT may be applied to study 
mechanisms of bacterial pathogenesis, through the lens of the causative agent of Lyme 
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Chapter 1: Functional Profiling of the Microbiota 
 
This chapter contains text that was first published essentially in this form in: 
Rosen CE, Palm NW. Functional Classification of the Gut Microbiota: The Key to 
Cracking the Microbiota Composition Code. Bioessays. 2017 Dec;39(12). doi: 
10.1002/bies.201700032. Epub 2017 Oct 4. PMID: 28976007. 
 
Abstract 
 The last decade has seen an explosion of research on the gut microbiota – the 
trillions of microorganisms that colonize the human gut. It is clear that interindividual 
diversity in microbiota composition plays an important role in determining susceptibility 
to a wide variety of diseases and disorders. However, identifying the precise changes in 
microbiota composition that play causal roles has remained a largely unrealized goal. Here, 
we propose that functional classifications of microbes based on their interactions with and 
effects on the host – particularly the host immune system – will illuminate the role of the 
microbiota in shaping human physiology. We outline the benefits of ‘functional’ 
classification compared to phylogenetic classifications, and review current efforts at 
functional classification of the microbiota. Finally, we outline a theoretical framework for 
classifying host-microbiota interaction. Future advances enabling broader functional 
classifications of the microbiota will revolutionize our understanding of the role of gut 




 We are constitutively colonized by trillions of microorganisms at all mucosal and 
barrier surfaces. These organisms, which are collectively referred to as the microbiota, span 
all kingdoms of life, including fungi, viruses, archaea, protists, multicellular eukaryotes, 
and bacteria (the most well understood and studied). The gastrointestinal tract contains the 
largest number and greatest diversity of microbes: healthy humans harbor over 1014 
bacterial cells. representing hundreds of species, which encode 150 times more genes than 
the human genome.[1] The microbiota also exhibits extensive inter-individual diversity—
each individual contains a unique consortium of hundreds of bacterial species and strains, 
and human gut microbial communities can vary between individuals at the phylum level, 
which is the taxonomic level that separates humans from jellyfish.[1] 
In the last decade, a torrent of evidence has illustrated the role of the intestinal 
microbiota in various host processes including glucose tolerance,[2, 3] chronic malnutrition 
and obesity,[4, 5, 6] autoimmune diseases including type I diabetes [7], inflammatory bowel 
disease (IBD) [8], and others [9, 10], inflammatory bone disease and osteoporosis [11], drug 
metabolism [12], neuronal development and function (the “gut-brain axis”) [6, 13, 14], and 
enhancing the efficacy of various cancer therapeutics [15, 16] . Despite this overwhelming 
evidence for the role of microbiota composition in health and disease [17], it has remained 
challenging to identify the precise changes in the microbiota that are responsible for 
mediating these powerful effects, and this remains a major goal of the microbiota field. 
Here, we will review the fundamental biological and technical roadblocks that have 
contributed to this difficulty, and propose a theoretical framework for classifying members 
of the microbiota that we believe will eventually allow us to achieve this goal. Critically, 
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such an understanding is a necessary first step towards the rational development of 
microbiota-targeted therapeutics. 
 
2. Theoretical challenges in identifying ‘causal’ members of the microbiota 
 Over a century ago, Robert Koch proposed four criteria to establish a causal 
relationship between a given microbe and disease. Koch’s postulates remain the ‘gold 
standard’ for demonstrating the infectious origin of disease. In their most basic form, 
Koch’s postulates require that a ‘causal’ microorganism fulfill four main criteria: (1) it 
must be present in all sick individuals and absent in all healthy individuals; (2) it must be 
isolated specifically from sick individuals; (3) administration of a pure culture of this 
organism must cause disease in a previously healthy individual; and (4) this organism must 
be re-isolated from the recipient where it caused disease and be shown to be identical to 
the originally isolated organism. Since their original proposal, Koch’s postulates have been 
repeatedly revised, taking into account phenomena such as healthy (asymptomatic) 
carriers, insights from nucleic acid sequencing, and even adapted to explain the role of 
specific virulence factors in disease (i.e., molecular Koch’s postulates) [18]. 
 While Koch’s postulates have been invaluable for demonstrating the microbial 
origin of infectious disease, applying these same principles to diseases that are potentially 
controlled by the microbiota has remained challenging for a variety of reasons. First, the 
role of the microbiota in disease often appears to depend on the relative balance of ‘good’ 
and ‘bad’ bacteria (or, in immunological terms, inflammatory versus immunoregulatory 
bacteria) in the gut, rather than the specific presence of a single ‘pathogen’ (Figure 1.1a). 
Therefore, the presence of a ‘bad’ bacterium can be countered by the effects of a ‘good’ 
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bacterium; this immediately violates the first of Koch’s postulates. This observation has 
given rise to the theory of ‘dysbiosis’ – i.e., that ‘imbalances’ in microbiota composition 
drive disease states (reviewed in [19, 20, 21]). Importantly, an individual bacterial taxon may 
be ‘good’ in one situation, but ‘bad’ in another – for example, segmented filamentous 
bacteria (SFB) can protect wild type mice from enteric infection, but also can exacerbate 
autoimmune arthritis [9, 22]. These differences can dependent on a myriad of factors, 
including host-genetics and health status, microbial location, and the surrounding microbial 
community, further complicating efforts to describe a single bacterium as ‘good’ or ‘bad’, 
and re-emphasizing the importance of a ‘balanced’ community. Second, it is highly 
unlikely that complex diseases with diverse manifestations, such as inflammatory bowel 
disease, are caused by a single ‘pathogenic’ organism. Instead, there are likely a variety of 
indigenous microbes that contribute to disease susceptibility population wide. Third, 
mouse models of disease have demonstrated that even phylogenetically divergent bacterial 
species (e.g., one from the phylum Bacteroidetes and one from Firmicutes) can drive the 
development of ostensibly identical disease states, such as bacterial-driven colitis (Figure 
1.1b) [8]. Fourth, different strains of the same bacterial species can have divergent effects 
on host physiology and disease susceptibility due to strain variation (Figure 1.1c) [23]. 
Finally, even the same strain of bacteria may exert distinct effects on the host depending 
on environment, location, or host-genetics – for example, metabolic effects of fecal 
transplant into germ-free mice depend upon the recipient strain, even when the same donor 
microbiota is used [24].  
Taken together, these challenges suggest that a reevaluation of our current 
approaches to understanding the role of the microbiota in disease may be necessary moving 
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forward. Thus, we propose a renewed focus on microbial functions and posit that this 
viewpoint, rather than a classical phylogeny-based approach, will eventually allow us to 
‘crack’ the microbiota composition code. 
 
3. Technical challenges in identifying ‘causal’ members of the microbiota: 
Limitations of taxonomy-based microbiota profiling 
In addition to these theoretical challenges, a number of technical challenges have 
hampered current efforts to understand the role of the microbiota in disease. The 
microbiome explosion has been driven largely by advances in next-generation sequencing 
(NGS), which have enabled rapid, accurate, and inexpensive profiling of complex 
microbial communities. By far the most common microbiota profiling method is based on 
sequencing of the gene encoding the small subunit of ribosomal RNA (16S). 16S rRNA 
gene sequencing has revolutionized the microbiome field by enabling nearly any lab to 
determine the taxonomic composition of a given sample cheaply and easily. However, it 
has also become clear that inherent limitations of 16S rRNA gene sequencing, and 
taxonomic classifications in general, may limit its ability to reveal the role of the microbiota 
in host physiology. 
Taxonomic classifications of the microbiota are clearly useful for understanding 
intra- and inter-individual diversity in microbial composition [25]. Furthermore, insofar as 
function correlates with taxonomy, 16S rRNA gene sequencing can also begin to reveal 
the role of particular microbes, as certain effects on the host can vary predictably across 
taxonomic groups [26]. However, it has become increasingly clear that taxonomy alone is 
often insufficient to determine microbial function. The most extreme case of this 
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disconnect is in the case of strain variation—the observation that different strains of the 
same species can have distinct, and sometimes opposite, effects on host physiology. For 
example, distinct strains of the model symbiont Bacteroides fragilis vary broadly in their 
effects on the host—some strains are tolerogenic due to the expression of the symbiosis 
factor polysaccharide A (PSA) [27], some ‘inert’ bacteria with no clear effects on host 
physiology, and some highly pathogenic due to the expression of B. fragilis toxin (Figure 
1.1c) [23].  
Because of the limitations of taxonomy-based classification systems for studying 
the microbiota, alternative approaches to defining the community composition and its 
effects on the host are necessary. We suggest that a focus on the functions performed by 
particular microbes will provide a classification scheme that will provide important insights 
into how microbiota composition shapes host physiology. Below, we will address two 
broad classes of ‘functional profiling’ of the microbiota. First, we will discuss ‘omics’-
based methods for functional classification of the microbiota, using metagenomics and 
metabolomics as representative examples of this class of methodologies. Second, we will 
discuss emerging methods for targeted functional profiling of the microbiota, with a focus 
on an immunological profiling technique that we recently developed called IgA-Seq. 
 
4. Microbial ‘functions’ 
Before we discuss functional profiling approaches, it is important to outline how 
we define a microbial function. For the purpose of this perspective, we will use the term 
‘function’ to refer to both activities of microbes (chemical or biological processes initiated 
or performed by a microbe) as well as characteristics of microbes (intrinsic and/or passive 
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microbial descriptors) that have a defined effect on host physiology. In other words, 
microbial functions describe any feature of a microbe, active or passive, and qualitative or 
quantitative, that impacts the host. Dozens of microbial functions with profound effects on 
host physiology have been identified, and many more certainly remain to be discovered 
and described – a non-comprehensive list of recently described functions are outlined 
below. The known impacts of microbiota functions on the host have been excellently 
reviewed elsewhere [21, 28-30, 31]. We will thus focus instead on how classifying the 
microbiota based on these functions provides unique insights into the effects of the 
microbiota on the host. 
 
Treg induction [23-26,28-30] 
Th17 induction [9,27,31,32] 
Local IgA induction [33] 
Response to immunotherapy [16,17] 
Alteration of bone mass [11] 
Anti-microbial activity [34,35] 
Production of functional small molecule metabolites [5,36] 
LPS structure [37,38] 
Antigen-specific IgA coating [8] 
Niche colonization / localization [39,40] 




Table 1.1: Known Functions of Members of the Microbiota 
 
 
5. Functional classifications of the microbiota 
We will discuss two classes of functional classifications (Figure 1.2b). First, we 
will address ‘omics’-based approaches, such as metagenomics and metabolomics, which 
enable functional classifications of the microbiota based on gene content and metabolic 
functions. These approaches reveal the presence and abundance of previously identified 
functions within a community through comparison to annotated databases. Second, we will 
introduce a complementary class of functional profiling approaches that we refer to as 
‘targeted’ functional profiling, which is typified by a technique that we recently developed 
to profile microbial interactions with the immune system called IgA-Seq [8]. Importantly, 
unlike omics approaches, targeted functional profiling approaches generate new functional 
information (annotations) that can be assigned to specific microbial taxa. 
 
6. ‘Omics-based’ Functional Profiling 
Unlike 16S rRNA gene sequencing, which reveals simply ‘who is there’, systems-
level ‘omics’ approaches can begin to reveal ‘what they are doing’. A wide variety of 
‘omics’ approaches have been applied to studies of host-microbiota interactions, including: 
shotgun metagenomics—sequencing of the complete genetic material encoded by a 
microbial community; metatranscriptomics—sequencing all of the RNA produced by a 
microbial community; metaproteomics—profiling all of the proteins produced by a 
microbial community; and metabolomics—profiling all of the small molecules produced 
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by a microbial community [48].Many recent studies have also begun to employ multi-omics 
approaches (i.e., integrating multiple omics approaches) to more completely characterize 
the activities of microbial communities [7, 49]. Because omics approaches have been 
excellently reviewed recently elsewhere [17, 48, 50, 51], we will largely restrict our discussion 
to metagenomics and metabolomics as representative omics-based approaches since the 
general strengths and limitations of these approaches apply to all ‘omics’ based approaches. 
The ability of various ‘omics’ approaches to reveal the role of the microbiota in 
human health and disease has been highlighted by a number of recent studies and reviews 
[2, 5, 49, 52, 53]. In particular, ‘omics’ approaches provide an unbiased assessment of microbial 
functions and generate large amounts of data that can inform future hypothesis-based 
experiments. Furthermore, recent advances in computational biology have greatly 
improved the sensitivity, speed, and applicability of omics-based analyses of microbiome 
data [26, 54]. Overall, the enormous utility of multi-omics approaches combined with 
sophisticated computational analyses to reveal the roles of microbial communities in 
human health and disease is now abundantly clear [5, 41, 53, 55]. However, a number of 
inherent limitations of these approaches continue to restrict our ability to fully reveal the 
role of the microbiota using ‘omics’ approaches alone. 
 The major limitation of ‘omics’-based profiling is its dependence on prior 
functional annotations, which only exist for a minority of genes, proteins, and metabolites 
encoded by host-associated microbial communities. For example, only 25% of observed 
genes in the microbiome are annotated, and another 25% are annotated by homology only 
[51, 56-58]. Furthermore, the majority of annotated genes belong to large classes of gene 
families that perform essential metabolic functions, whereas genes encoding proteins that 
 17 
mediate specific host-microbiota interactions remain mostly uncharacterized [51, 59]. These 
well-understood metabolic gene families show low interindividual variability within the 
human population and are therefore unlikely to contribute to differential disease 
susceptibility among individuals [57]. Since the gut microbiome of an individual human 
contains more than 150 times more genes than the human genome and each individual 
possesses a unique microbiome [56], determining the functions of all of these genes is a 
daunting task. Finally, metagenomics only illustrates potential functions, as specific genes 
may not be actively transcribed in certain in vivo settings [48]. To reveal realized functions, 
metagenomics must be combined with metatranscriptomics or metaproteomics. 
Current functional annotations of shotgun metabolomic data are even poorer than 
functional annotations of metagenomic data. While targeted metabolomics approaches can 
sensitively detect and quantify metabolites that are already well understood and have 
known effects on host physiology, the physiological effects of the vast majority of 
biosynthetic gene clusters and individual metabolites remain completely uncharacterized 
[3, 17, 38, 60, 61]. Indeed, at this stage it is difficult to even determine the total number of 
metabolites produced by the gut microbiota, let alone to annotate all of their functions.  
Metagenomics and metabolomics illustrate the strengths and limitations inherent in 
‘omics’ approaches, which are shared by other methods such as metatranscriptomics and 
metaproteomics (excellently reviewed elsewhere, [17, 48]). Most importantly, all of these 
methods rely on prior annotations in order to assign functions to a given gene, protein or 
metabolite. 
 
7. New methods for ‘targeted’ functional classification 
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We suggest that the limitations of taxonomic and omics-based profiling can be 
overcome by combining these approaches with new methods for ‘targeted’ functional 
profiling to enable assignment of new functions to specific bacterial taxa. Targeted 
functional profiling methods should satisfy several criteria. First, they should assign 
functions to taxa independent of prior annotations. Second, targeted functional profiling 
approaches should be agnostic to taxonomic labels, and therefore identify taxonomically 
divergent microbes that encode shared functions and distinguish between strains of the 
same species that encode different functions. Third, targeted profiling should offer a 
measure of bacterial importance that is independent of bacterial abundance; this can be 
particularly useful for taxa that are rare in fecal samples, but may play outsized roles in 
shaping host physiology. 
 
 
7.1. Immunological profiling of the gut microbiota: IgA-Seq 
One of the major mechanisms by which the gut microbiota influences host 
physiology is through its interactions with and effects on the immune system [28, 29]. For 
example, specific members of the murine gut microbiota that interact intimately with the 
immune system in the gut, such as Helicobacter species and Segmented Filamentous 
Bacteria, can exacerbate the development of inflammatory diseases in the intestine (e.g., 
Inflammatory Bowel Disease) and at distal sites (e.g., autoimmune arthritis) [9, 62]. A unique 
feature of the immune response at mucosal surfaces is the production and secretion of 
immunoglobulin A (IgA) [28, 63]. IgA is unique among antibody isotypes in that it is 
primarily secreted into the intestinal lumen, where it can bind to and coat target bacteria. 
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Effective IgA responses are essential to maintain a ‘healthy’ microbial composition in the 
gut—in the absence of appropriate IgA responses, mice develop dysbiosis and exhibit 
increased susceptibility to inflammatory disease [64, 65]. IgA can be produced through T-cell 
independent or T-cell dependent mechanisms. T-dependent IgA is generally higher affinity 
and targets more ‘highly pathogenic’ (invasive, aggressive, or damaging) microbes, 
providing protective immunity [63], while T-independent IgA is generally lower-affinity 
antibody reactive against common microbial epitopes, which provide homeostatic 
functions in controlling the extent of commensal interaction with the host epithelium and 
mediating mucosal adhesion and selection [63, 65].  
In order to identify specific bacterial taxa that interact intimately with the immune 
system and, therefore, induce high-affinity IgA responses, we developed a functional 
profiling technique called IgA-Seq. Briefly, IgA-Seq combines fluorescence activated cell 
sorting and 16S rRNA gene sequencing to quantify Immunoglobulin A responses to the 
intestinal microbiota in a taxa-specific manner (Figure 1.2a) [8]. IgA-Seq typifies the 
‘targeted’ functional profiling approach by identifying specific microbes in the gut that 
induce high-affinity, antigen-specific immune responses. Using IgA-Seq, we can focus in 
on the bacterial species in each individual that likely play a major role in shaping host 
immunity and susceptibility to inflammatory disease. 
In the first application of this approach, we showed that IgA responses to the 
microbiota in humans with inflammatory bowel disease marks putative disease-driving 
bacteria that uniquely confer disease susceptibility when transplanted into germfree mice; 
thus, IgA-coating identifies putative causal organisms in IBD that would not have been 
identified simply using phylogenetic or omics approaches (Figure 1.1b) [8]. IgA-Seq has 
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subsequently been used to identify microbes involved in both metabolic disease and 
extraintestinal manifestations of IBD: IgA-coating was used to identify organisms that 
contribute to the pathophysiology of severe malnutrition [43] and pathogenic strains of E. 
coli present in a subset of Crohn’s disease patients that have a unique functional role in 
inducing Th17 cells that may drive peripheral spondyloarthritis in these patients [66]. These 
results suggest that IgA-Seq will be useful for identifying disease-modulating organisms 
in a variety of diseases and disorders.  
The example of IgA-Seq highlights several advantages of targeted functional 
profiling as discussed above. IgA-Seq assigns function without reliance on prior 
annotation. Second, IgA-Seq can distinguish between strains of the same species that differ 
in their ability to induce an immune response, and identifies all bacterial species that are 
able to do so – it is agnostic to taxonomic labels. Finally, it can identify bacteria that are at 
low measurable abundance but play an important role in host physiology - for example, 
segmented filamentous bacteria (SFB) are incredibly rare in mouse feces, but play a major 
role in shaping both intestinal and extra-intestinal immunity [9, 22]; accordingly, SFB shows 
the highest level of IgA coating in the gut by IgA-Seq [8].  
 
7.2. Non-immunological targeted functional profiling 
 Another example of targeted functional profiling we recently described applies the 
PRESTO-TANGO system for profiling GPCR activity[73] to systematically characterize the 
GPCR-agonist activity of microbially derived metabolites. This “forward chemical genetic 
screen”[74] revealed dozens of novel GPCR-active small molecules produced by individual 
microbes in culture. These include widespread production of succinate, production of 
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bioactive amines, and biotransformations of simple dietary amino acids. We then illustrated 
the bioactivity of several of these metabolites to shape local (colonic motility) and systemic 
(CNS phenethylamine accumulation) physiology in the host. This functional profiling 
approach builds on similar investigations of individual metabolites[75], and again reflects 
the ideal goals of a functional profiling approach – independence of taxonomic labels or 
prior gene annotation, and application to bacterial isolates regardless of abundance. 
Additional targeted functional profiling approaches continue to emerge and have 
proven to be powerful tools to uncover the various functions of specific microbes when 
combined with taxonomic or omics based profiling. For example, cell sorting based on 
bacterial viability enables functional profiling of the ‘active’ fraction of the microbiota, 
and revealed the impact of xenobiotics on specific microbial taxa from the gut microbiota 
[67]. Furthermore, a novel computational approach to the analysis of transcriptomic data 
(Peak to Trough Ratio; PTR) allows for functional profiling of growth rates in a taxa-
specific manner, which is particularly useful when following microbial responses to a 
changing environment such as alterations in diet or during infection [68]. Finally, functional 
metagenomics studies, where fragments of metagenomic DNA are expressed in a surrogate 
host to identify genes involved in a specific bacterial activity or function, have enabled 
discovery of unannotated genes that confer specific functions [69] – for example, the 
identification of bacterial factors that improve in vivo fitness in a competitive setting [70]. 
One recent study employing a variation of functional metagenomics expressed predicted 
nonribosomal peptide synthetase (NRPS) gene clusters identified in a wide range of gut 
microbial genomes in genetically tractable model organisms (E. coli and B. subtilis), 
identified new molecules produced from expression of these gene clusters, and confirmed 
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their serine-protease inhibitory activity [71]. This study demonstrated a new function of the 
microbiota that could be measured without reliance on prior annotation (while the authors 
used bioinformatics and sequencing approaches to initially identify the NRPS gene 
clusters, the function was not identified in an annotated database), could be agnostic to taxa 
labels (each sequence expressed could be tied back to a single source strain, and distantly 
related species could be identified through the same screen), and is independent of bacterial 
abundance. This further illustrates how targeted functional profiling methods have the 
ability to generate new biological hypotheses and discover new roles of the microbiota in 
controlling host physiology. 
 
7.3. Targeted functional profiling: Limitations and future applications 
The above examples highlight the advantages of targeted functional profiling; 
however, these approaches are, of course, not without their own limitations. Most notably, 
these methods are generally lower-throughput than omics approaches, and are inherently 
limited by their focus on a single function of interest (e.g., immune activation in the case 
of IgA-Seq, or bacterial growth in the case of PTR). IgA-Seq, for example, is only useful 
insofar as the disease or physiological function of interest is related to 
inflammation/immunity at mucosal surfaces. Profiling of the complete spectrum of 
functions of a microbial community will therefore require multiple, non-overlapping 
functional analyses.  
Future development of additional targeted profiling approaches promises to further 
enable mechanistic studies and greatly expand research in the microbiota field. For 
example, a recent study found that differences in LPS structure between members of the 
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microbiota may predict immunostimulatory activity, and that these differences in activity 
can influence the incidence of autoimmunity, building on a larger body of previous work 
illustrating the effects of LPS modification on immunostimulatory activity [41, 42, 72], and 
suggesting that examination of essential, but variable, bacterial features is important for 
determining disease susceptibility and may be a good candidate for targeted functional 
profiling. Other phenotypes known or expected to be connected with host-microbe 
interactions, such as spatial location within the gut and mucus association, should also 
prove to be fruitful ground for high-throughput functional profiling of microbes. 
 An ultimate goal of targeted functional profiling will be to group gut microbes into 
categories based on their effects on the host rather than their phylogeny or gene content. 
Such a classification will be essential to elucidate shared bacterial mechanisms and host 
pathways engaged by diverse groups of microbes that mediate specific effects on host 
physiology. These common functions will provide strong candidate therapeutic axes for 
treatment of microbiota-mediated diseases which may be universal rather than specific to 
one bacterial species and/or subset of patients. 
 
8. Conclusion 
 We are growing to appreciate that the complexity and diversity of the microbiota 
can have wide-ranging and dramatic impacts on the host. However, we still lack the 
understanding of how the precise composition of the microbiota drives various health and 
disease outcomes – we have yet to “crack the microbiota composition code”. We propose 
that functional classification of microbes, relying on outcomes rather than phylogeny, and 
identifying easily-measurable correlates of function to enable high-throughput and rapid 
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profiling of microbiota communities will be key to achieving this goal and moving towards 































Figure 1. Microbiota Composition has Complex Impacts on Disease Susceptibility. (A) Community 
Composition Shapes Microbiota-Driven Disease. Rather than presence or absence of a single microbe being 
linked to disease, it is now understood that microbiota-driven diseases can result from altered community 
composition. Healthy individuals have a “balanced” microbiota, depicted as equal abundance of 
immunoregulatory (blue) species and inflammatory species (red, orange, and yellow). Gain of a novel 
inflammatory species (moving to the right) results in disease, despite the continued presence of the same 
immunoregulatory microbes, while loss of a immunoregulatory species (moving to the left) also results in 
disease, despite no new inflammatory phenotypes appearing. (B) Phylogentically Diverse Microbes Can 
Cause Similar Phenotypes. Koch’s postulates require the causative agent of a disease be the same among all 
afflicted individuals. However, it is known that a wide array of phylogenetically diverse microbes (depicted 
as red bacteria at different branches of a mock phylogenetic tree) can all be linked to or cause microbiota-
mediated diseases, such as IBD. (C) Distinct Strains of the Same Bacterial Species can have Opposite 
effects on Disease Susceptibility. The problem of strain variability within taxonomically ”identical” isolates is 
highlighted using three simplified examples of Bacteroides fragilis strains. Note that the strains can be highly 
(>90%) identical at the genomic level. Nonetheless, small differences in gene content can result in large 
functional differences. On the left, expression of genes necessary for synthesis of polysaccharide A (PSA) 
results in an immunoregulatory phenotype, while on the right side expression of a toxin results in an 
inflammatory phenotype.  
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Figure 2. Functional Profiling of the Microbiota. (A) IgA-Seq identifies immunologically-important members 
of the gut microbiota. IgA-Seq combines bacterial cell sorting and 16s rRNA gene sequencing to identify 
specific members of the microbiota that are coated with the secreted immunoglobulin IgA. Cells isolated 
from fecal samples are stained with anti-IgA antibodies and sorted based on their IgA coating. The IgA-
coated and uncoated fractions are then subjected to 16s rRNA gene sequencing to identify species that are 
enriched for IgA coating. (B) Functional classification of the microbiota. Select methods for functional 
classification of the microbiota, including representative ‘omics’-based approaches (metagenomics and 
metabolomics), and targeted functional profiling (IgA-Seq) are depicted. Metagenomics identifies microbial 
taxa and genes present in a microbial community, metabolomics identifies the various small-molecule 
compounds produced by the microbial community, and IgA-Seq identifies particular microbes that interact 
intimately with the mucosal immune system. Omics approaches and targeted functional profiling approaches 
possess complementary strengths and weaknesses. Omics approaches are generally unbiased, high-
throughput, and high-content, but depend entirely on prior annotations to assign functional activities; in 
contrast, targeted functional profiling approaches can create new functional assignments to specific genes or 
taxa, but are generally restricted to examining a single function at a time.  
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Chapter 2: Selection and Pressure on the Microbiota 
 
To identify the role of host-microbe interactions in shaping the microbiota, it is 
necessary to understand the selective pressures acting on microbes and the alternative 
mechanisms of overcoming or adapting to these pressures. The first portion sets the stage 
by discussing the basic features of bacterial life as they relate to growth and death. Next, 
the environmental challenges associated with life in the intestine are discussed, moving 
from the tissue-specific feature of peristalsis to the competitive features present in any 
population of mixed microbes. Finally, there is a brief discussion of the effects of the host 
immune system on the microbiota, as a distinctive environmental factor shaping host-
associated microbial communities. 
 
Growth and death 
The mammalian intestine presents a wide range of physicochemical conditions that 
bacteria can explore to find an optimal niche. These include longitudinal and transversal 
variations in pH, exposure to oxygen or other gases, and host- or diet-derived molecules1. 
In many cases, it is difficult to appropriately model these features in an in vitro system to 
adequately measure even simple features such as bacterial growth and death rates. Even if 
an adequate system is identified to study bacteria in one setting, there may be variability in 
bacterial lifestyle in a different location or at a different time in the gut2. It therefore 
remains a generally open question what the exact physiology of bacteria is in situ. 
Nonetheless, a variety of quantitative assessments broadly suggest that bacterial 
growth in the intestine or other human-associated environments is substantially slower than 
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optimal growth in in vitro systems. Methods including dye-tracing (which tracks number 
of cell divisions)3, ribosomal hybridization (a readout of cell proliferation capacity)4, 
colony counts5, inference from mutation rates, or calibration of metagenomic “peak-to-
trough ratios”6 often reflect slower growth in situ when compared to the fastest growth 
rates achievable in monoculture conditions. In some cases, these measurements reflect the 
combined growth and death rates of the bacteria, but even isolation of precise growth rates 
alone still identifies a relatively slow growth rate in vivo, with doubling times of several 
hours even for microbes such as E. coli which can grow an order-of-magnitude in liquid 
culture. Rates following colonization of previously-germ free animals can reflect faster 
growth rates7, but have not been rigorously compared to steady-state growth rates across a 
range of microbial species. 
Importantly, many of these measurements still leave the question of bacterial cell 
cycles in situ unclear. It is not universally known whether in situ growth is best represented 
in lag phase, early/mid/late logarithmic phase, stationary phase, or an alternative cell state 
not well captured in a standard logistic growth model. In particular, many of these methods 
may fail to capture “maintenance” or “survival” states of microbes, metabolic states that 
have been identified in a wide range of environmental microbes8. In these states, energy 
consumption orders of magnitude (up to 1000-fold) below that required for growth can 
sustain regulation of osmolarity, pH, and macromolecular quality control mechanisms, in 
the absence of DNA replication or biomass production necessary for cell division. Whether 
such dormant populations exist in vivo is an open question. It is an intriguing possibility 
that microbes in experimentally inaccessible niches (i.e. not readily sampled in feces), or 
those undetectable by sequencing-based approaches but known to be present (such as 
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opportunistic pathogens that show low-level carriage in healthy individuals before 
blooming under some external stimulus), might exist in such a metabolic regime, and 
therefore exhibit aspects of biology unlike any modeled in growth-enabling in vitro 
systems. 
The final question is how overall bacterial growth is built by the combination of 
intrinsic growth and death rates. Multiple studies comparing colony counts, which measure 
live cells, with total cell count measures have suggested that the vast majority of intestinal-
resident cells are alive (specifically, able to form colonies on appropriate media). This is 
in agreement with growth models based on population dynamics of trackable engineered 
strains, which suggested that steady-state growth is characterized by a slow death rate 
relative to initial colonization dynamics9. 
 
Peristalsis 
 The total bacterial population is also impacted heavily by elimination of cells, 
regardless of their growth or metabolic status. In the intestine, a critical mediator of cell 
removal or elimination is the longitudinal liquid flow, driven by host peristalsis. Precise 
flow rates vary both temporally and longitudinally along the gastrointestinal tract10. 
Estimates of flow rate based on fluid elimination suggest minimal average flow rate of 20 
µm/s in the human colon11. This is comparable to the maximal chemotactic speeds 
observed for a variety of gut microbes. Thus, in order to combat peristalsis purely by 
motility, bacteria would need to dedicate a substantial portion of their energy to directed 
migration “upstream”, and non-motile bacteria would be rapidly eliminated. Therefore, it 
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seems unlikely that bacteria avoid elimination purely or even primarily through intrinsic 
motility. 
 Theoretical and experimental modeling suggests that intestinal contractions create 
sufficient mixing and “backflow” to maintain bacterial density10,11. This mixing may be 
largely responsible for maintaining the overall bacterial population within the gut, in spite 
of the low growth rates that would seem incompatible with dramatic removal pressures. 
However, at the level of an individual microbial population, peristalsis still represents a 
strong selective pressure. This is most well illustrated by detailed investigation of the 
zebrafish microbiota, where the population may be readily imaged and monitored over 
time. In that setting, it has been clearly demonstrated that populations more vulnerable to 
physical removal – particularly bacterial aggregates that are subjected to different fluid 
forces – are readily removed from the intestinal tract and show strong fitness defects 
relative to comparably growing but more dispersed microbes12-15. 
 Another mechanism for avoiding the pressures applied by peristalsis is to reside in 
sheltered niches of the gut. In particular, adhesion to host surfaces (mucus or directly to 
epithelial cells) would theoretically enable microbes to avoid removal by peristalsis. While 
an attractive hypothesis, it is unlikely that this accounts for the major source of bacterial 
repopulation in the face of flow-based removal. Modeling suggests that even if the mucus 
layer were fully colonized at the maximal achievable density, the bacterial population 
resident there would be unable to replace those cells removed due to flow at maximal 
achievable growth rates, let alone the slow observed in situ growth rates. However, for an 
individual microbial species, adhesion may offer a sufficient “reservoir” for maintenance 
of the population, based on the particular growth and death rates for that microbe. In 
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particular, adhesion (or close host association) offers the potential for access to unique 
host-derived signals or nutrients, and therefore the local growth rate may be different from 
the bulk population growth rate16. It will be critical to quantitatively examine bacterial 
population dynamics in situ to understand the relative contributions of mixing, motility, 
luminal growth, and replenishment from host-associated subpopulations in maintenance of 
bacterial cell numbers, although it is clear that most of these are individually insufficient 
to maintain the global microbiota density in the gut. 
 
Direct Competition 
 The above sections have focused on intrinsic properties of microbial lifestyles in a 
dynamic environment, considered in isolation. However, the intestinal microbiota is 
comprised of hundreds of strains that may compete for spatial or nutritional niches. As in 
other complex microbial communities, a wide range of direct antagonistic mechanisms are 
used by intestinal microbes to gain competitive advantages over other community 
members. These include a range of contact-dependent mechanisms, as well as the 
production of soluble anti-microbial effectors. 
 Dominant forms of contact-dependent microbial competition include contact-
dependent inhibition (CDI) systems and type 6 secretion systems (T6SS), both of which 
are abundant among gram-negative bacteria17,18. Both deliver toxins to target cells through 
a large surface-associated complex, although the mechanistic details differ. Examples of 
competitive advantages for CDI- or T6SS-expressing strains over similar microbes in the 
mammalian gut environment illustrate that the density, localization, and mixing of 
microbial populations is sufficient to enable complete depletion of non-competitive 
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strains19-21. Importantly, metagenomic analyses have also illustrated widespread carriage 
of immunity proteins that protect against T6SS-delivered toxins even in the absence of 
T6SS effectors, suggesting that potential intoxication is a sufficient danger to drive long-
term maintenance of protective genes22. While contact-dependent inhibition systems have 
been identified in gram-positive microbes, their presence and fitness advantages in the 
microbiota have not been evaluated, but it is likely they may play similar roles in shaping 
gram-positive microbial communities23. 
 Bacteria also produce a wide range of soluble anti-microbial molecules, especially 
peptide derivatives and small proteinaceous toxins17. These include nonribosomal peptides 
(NRPs) as well as ribosomally synthesized post-translationally modified peptides (RiPPs), 
which include bacteriocins, lantibiotics, and microcins. Production of both NRPs and 
RiPPs has been noted in the human microbiota, across a range of species, and evidence 
exists for a competitive fitness advantage in antibiotic NRP/RiPP producers24-27. While 
these are soluble molecules and can therefore act at a distance, it is important to consider 
the physical limits on the reach of these molecules (see Appendix, below). The relatively 
low inhibitory potential of these molecules (i.e. >>1 µM)26 prohibits their production in 
inhibitory concentrations even in a static setting at distances much beyond ~1mm. Thus, 
these small molecules still likely act microscopic regions to enable local competition in a. 
defined spatial niche, rather than shaping global tissue microbial composition in a wide-
reaching fashion unless produced across a wide area of the intestine. 
 
Nutrient Acquisition and Metabolic Networks 
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 A critical determinant of microbial fitness in the intestine is the ability to acquire 
and utilize specific nutrients. These may include simple or complex carbohydrates, amino 
acids, steroids, lipids, metals, and a variety of other small molecules required as metabolic 
precursors or cofactors28. The sources of these molecules may include host diet, host-
derived molecules, and byproducts from other microbes. Tremendous variability exists in 
preferences for metabolic substrates within and across phylogenetic groups, including the 
ability to uptake and break down complex carbohydrates and polysaccharides as well as 
the relative utilization efficiencies of simple sugars for energy production. Nonetheless, it 
is clear that in a wide range of cases, expansion of metabolic niches is one of the strongest 
competitive advantages available to microbes in the gut. 
 Extensive work on polysaccharide utilization loci (PULs) in Bacteroides species 
and strains has provided a useful example of the advantages provided by an expanded 
metabolic niche29. Strains may harbor dozens of PULs, often comprising homologs of the 
outer membrane starch binding protein and transporter SusC/D along with hydrolases that 
break down the polysaccharide either extracellularly or after uptake. A variety of genetic, 
biochemical, and structural studies have illustrated how PULs may discriminate between 
sugars and enable growth in a variety of nutrient conditions30-36. In particular, acquisition 
of PULs that enable unique utilization of a polysaccharide can provide dramatic advantages 
in vivo, most notably illustrated by the example of a porphyran utilization locus37. 
Controlled administration of dietary porphyrin, in the form of seaweed, enabled rapid and 
substantial growth, up to 10,000-fold in a single day. Notably, this is comparable to the 
measured in vitro growth rate on porphyran as a sole carbon source, with a doubling time 
of ~100 minutes, and enables growth to extremely high densities approaching 1011 cells/mL 
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(the approximate density of the total intestinal microbiota). This suggests that a major 
limiting factor in bacterial growth in vivo is nutrient availability, and relief from that 
pressure by removal of diet-imposed limits or metabolic competition enables near-maximal 
growth potential. Similarly, removal of a preferred nutrient substrate can result in rapid and 
near-complete elimination of bacterial strains from the gut. Observations of the clear fitness 
advantages imparted by individual metabolites have also been shown for nucleotides and 
metal-containing vitamins in gut Bacteriodes strains38-40. Numerous studies have also 
illustrated the ability for host-derived molecules to support individual microbes during 
homeostasis or periods of inflammation41-43, reinforcing that nutrient availability, 
regardless of source, is a key determining factor for microbial growth. 
 These studies have illustrated the critical role of nutrient acquisition in bacterial 
fitness in the gut. In a complex environment colonized by many species of microbes, as in 
the gut, competition between microbes for common substrates and cooperation through 
sharing of metabolic byproducts both enable growth patterns that do not necessarily reflect 
fitness or growth capabilities in isolation. Metabolic exchange in complex microbial 
communities has been measured in simplified experimental systems44 and modeled through 
computational methods such as flux balance analysis (FBA), which uses genome-scale 
metabolic reconstructions to balance input and output through multiple metabolic pathways 
from a variety of microbial community members45. Importantly, modeling and 
experimental investigations have suggested that metabolic exchange may only be stable if 
there are sub-optimal growth rates for many community members46,47. This is a critical 
observation in line with the observed slow growth rates in situ (discussed above) and the 
overall stability of the microbiota. Taken all together, the most plausible in vivo scenario 
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for the microbiota under homeostatic conditions is an environment in which most nutrients 
are limiting for most species, metabolic competition between closely related microbes 
enforces metabolic niches, and extensive metabolic exchange supports and stabilizes the 
complex community. This has been recently supported by the demonstration that 
ecologically connected communities assemble in a predictable manner and order, related 
to co-dependent interactions between microbes, during neonatal colonization, and that 
host-derived nutrients support community assembly. 
 
The Host Immune System 
 A unique environmental challenge of tissue colonization is the direct action of the 
host immune system and its ability to exert untargeted or targeted effects on the resident 
microbial community. In the intestine, a dominant mechanism of immune targeting is the 
production of large quantities of IgA, the most highly produced antibody isotype in the 
body48. IgA can be produced through T-dependent and T-independent pathways. While T-
independent IgA, often targeting polymeric structures such as lipid or glycan components 
of cell membrane and cell walls, can coat a wide range of microbial species, the dominant 
source of specific IgA coating of highly targeted strains appears to be T-dependent. T-
dependent IgA production, accompanied by extensive somatic hypermutation that can 
increase affinity, specificity, or cross-reactivity, enables selective shaping of the microbiota 
by the host immune system. Interestingly, antibody binding can shape the microbiota 
through both positive and negative effects on the targeted microbes. For example, 
“enchaining” that causes targeted bacteria to clump together leads to increased removal by 
peristalsis (as discussed above)49, while IgA binding can also provide beneficial nutrients 
 48 
to microbes to support their growth50,51. The importance of IgA is reinforced by multiple 
mechanisms evolved within the microbiota for binding, cleaving, or inducing IgA 
production by the host52-54. 
 IgA is a major player in immune-microbiota interactions, due to its secreted nature, 
high concentration, and breadth of targeting capabilities. Several grams of IgA are secreted 
into the gut each day, sufficient for more than a thousand-fold excess of IgA molecules to 
bacterial cells in the gut. Numerous other secreted antimicrobial proteins and peptides can 
also shape the microbiota, and the evidence of their selective pressure can also be shown 
through adaptation of gut resident microbes to avoid targeting through modification of 
targeted structures such as cell membrane composition55. 
 While IgA and other secreted molecules are well appreciated as potential immune 
mechanisms to shape the microbiota, there is clear but perhaps underappreciated potential 
for interaction with host immune cells. For example, luminal neutrophil infiltration is a 
common feature of inflammatory gut conditions, although fecal leukocytes can be detected 
even at baseline56-58. Intriguingly, human neutrophils express the receptor for IgA (FcaR1) 
and might therefore respond to coated microbes in the lumen, while mice lack an IgA 
receptor completely. Studies in mice may therefore neglect the ability of luminal 
neutrophils to act in a directed manner, guided by IgA coating. Myeloid cells can directly 
sample the contents of the lumen through protrusions that extend between epithelial cells59-
61, and intraepithelial lymphocytes reside in extremely close proximity to microbes62,63. 
The extent to which these cell types may also migrate across the epithelium and exert 
luminal actions remains unclear, but it is highly plausible that during conditions of 
intestinal inflammation, when barrier integrity may be diminished, or even at baseline 
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during rapid epithelial turnover, some of these cells may reach the lumen and respond 
directly to microbes there. 
 
Summary 
 Overall, the intestinal microbiota exists in a dynamic, challenging environment, 
where a variety of selective pressures drive microbial physiology and evolution. These 
include peristaltic flow, irregular nutrient availability and competition for metabolically 
essential molecules, direct antagonism from other microbes, and the directed and generic 
effects of the host immune system. Individual experiments have illustrated that any of these 
individually may be sufficient to mediate complete elimination of particular microbes, but 
their relative roles in shaping the global microbiome remain unclear. Importantly, direct 
interactions with host-produced molecules may provide microbes with avenues to mitigate 
all these pressures – whether by anchoring to host cells or structures to avoid flow-mediated 
expulsion, or cleavage / evasion of immune molecules.  
Appendix: Quantitative Estimations of Small Molecule Production in the Microbiota 
         Numerous aspects of bacterial activity in the gut are controlled by soluble small 
molecules, ranging from genuine small molecule metabolites (e.g. SCFAs, glucose) to 
small proteins such as bacteriocins. This appendix will briefly treat on the quantitative 
estimation of production and biodistribution of these molecules, using simple order-of-
magnitude calculations to provide a framework for boundaries on the potential roles of 
these molecules. Quantitative estimates are primarily derived from the Bionumbers 
database, with references provided for special values (Table 2.1). Broadly, these 
estimations suggest that microbially-derived small molecules must either a) act over small 
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distances, b) exhibit high potency, or c) be produced at scales comparable to central 
metabolic mediators. Thus, wide-reaching modestly potent molecules are likely 
fundamental metabolic byproducts. 
         The first analysis will focus on the production of small molecules. A suitable 
benchmark may be the production of ATP. Two independent analyses suggest that ATP 
production in E. coli occurs at a rate of approximately 107 molecules/cell/second – that is, 
each cell produces approximately 10 million ATP molecules per second. First, a value of 
~12 * 109 molecules of ATP is required to produce 1 cell. At a doubling time of 20 minutes 
(1200 seconds) for fast in vitro growth, this requires a production of 107 molecules/second. 
An alternative measure is the pre-cell production rate during growth on acetate – 
normalizing the production of 855 mmol/min/L to a cell volume of ~1.4 fL gives a value 
of approximately 107 molecules/cell/second. Thus, a useful benchmark to remember is that 
production of ATP can be reasonably estimated at 107 molecules/cell/second. This may 
serve as a useful upper limit for estimates of small molecule production, as this reflects the 
production of the major energetic currency of a cell under conditions of robust growth. It 
is unlikely that any molecule is likely to be produced substantially faster or in substantially 
higher levels. 
A useful check that this may reflect small molecule production capacity in the 
microbiota is given by measurements of acetate production, which suggest a rate of 
approximately 1018 molecules produced per second by the collective microbiota – requiring 
production of only 104 molecules/cell if all microbes are actively producing acetate, and 
only reaching the ATP estimation rate of 107/cell/s if 0.1% of microbial cells produce 
acetate. As a critical metabolic byproduct of fermentation metabolism by a range of 
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microbes, we see that this matches the upper limit imposed by ATP production and 
suggests that even metabolically critical molecules may be produced substantially below 
this rate. This is also consistent with observed average kcat enzymatic rates and protein 
abundances, which together suggest an average production rate of ~105 
molecules/cell/second for central carbohydrate metabolism. It is important to note that even 
alternative metabolic enzymes, such as those involved in intermediate metabolism, can be 
more than 10 times slower than central carbohydrate metabolism and expressed at lower 
levels. It has been additionally shown, at least for E. coli metabolic enzymes, that maximal 
in vivo apparent rates are comparable with in vitro calculated catalytic rates, suggesting 
these estimates are generally useful as maximal rates for cellular production. 
 How does production of non-metabolic small molecules of interest compare? These 
enzymes can be dramatically slower and expressed at substantially lower levels. For 
example, the production of erythromycin depends on the polyketide synthase DEBS, which 
has a kcat over 1000-fold slower than average central metabolic enzymes. At modest levels 
of protein expression, at the low end of metabolic enzyme levels, production may be 
limited to 10-100 molecules/cell/second. This illustrates that even important and bioactive 
molecules may be produced at what appear to be very slow rates on a per-cell basis. 
Do these values explain systemically relevant production by a limited number of 
microbes? Given per-cell production rates, it is straightforward to estimate the maximum 
achievable tissue concentrations of small molecules as a function of bacterial abundance. 
Figure 2.1 is a graph illustrating the maximal colonic concentrations achievable by 
microbes producing molecules according to a variety of the described rates. At the top, 
shaded in grey, are concentrations that would require rates of production greater than the 
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theoretical maximum of 107 molecules/cell/second. The blue range represents metabolic 
byproducts, showing central carbohydrate metabolic byproducts at the upper end and 
secondary metabolites at the lower end. At the lowest range, along the red line, is 
production at rates comparable to the slow estimated production rate of erythromycin. 
These estimates illustrate that high bioactive concentrations above 1 mM are readily 
achievable, but only for highly abundant microbes or small molecules produced at rates 
matching that of core metabolic programs (see the illustrated point, showing production of 
a secondary metabolite by a bacterium making up 10% of colonic bacteria). Specialized 
small molecules produced by lower abundance bacteria reach only modest concentrations 
in the colon (the second point, showing production at an erythromycin-like rate by a 
bacterium at 1% abundance). It is worth noting that, given perfect uptake, serum 
concentrations would reach 30-50% the indicated levels from the colon, owing to the 
volume differential, while small intestinal concentrations are likely to be ~1000-fold lower 
for an analogously producing population present there, given similar total tissue volume 
but greatly reduced bacterial population size. 
It is important to note that these are estimated maximum concentrations, based on 
a number of simplifying assumptions. The concentrations plotted are the maximal 
concentrations assuming once daily turnover of intestinal contents – time-averaged 
concentrations are therefore likely to be lower. Additionally, these concentrations neglect 
the requirement for export from the bacterial cell. While the export pathways for many 
small molecules are unknown, it is useful to note that the maximal uptake rate of glucose 
in E. coli is ~106 molecules/cell/second, which might serve as an estimate for maximally 
efficient transport – therefore limiting accumulation of the most abundant metabolites. 
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Precursors for metabolite synthesis may be unavailable under certain conditions based on 
host dietary intake or competition with other microbes, reducing the output rates even for 
the fastest metabolic enzymes. Diffusion limits the potential spread of small molecule 
metabolites, as diffusion times to cross distances greater than ~100 µm are slower than 
intestinal flow rates, preventing diffusion “upstream”, and distances greater than ~1 cm 
require diffusion times on the order of 1 day or longer, preventing macroscopic spread of 
a locally produced metabolite. This means that, in the absence of intestinal contractions 
that promote mixing (which may indeed serve to partially mitigate these effects), for a 
bacterial population in the center of the lumen of the large intestine, with a diameter of 
several cm, the concentration of small molecules that may reach the host is essentially 
negligible, even under the highest rates of production – while the concentration near those 
producers in the center of the lumen may be extremely high. 
While only crude estimates, these numbers illustrate the range of feasible 
production of bioactive small molecules by members of the intestinal microbiota. They 
align with observed capabilities of intestinal microbes, such as the production of high 
micromolar concentrations of serum IPA or TMAO derived from fundamental metabolic 
pathways of Clostridium species in a cell-concentration dependent fashion. Local 
concentrations may certainly reach above these estimates (concentrations in the 
flow/diffusion-limited local area of ~100 µm, or several dozen cell lengths, may be up to 
109 times higher than overall intestinal concentrations), and indeed suggest that the 
potential for microbes to influence their immediate microenvironment is readily achievable 
even with relatively slow production rates - explaining the potential evolutionary 
conundrum that even critical molecules may be produced at very low per-cell rates. 
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Property Bionumbers ID / reference Value 
ATP production rate on acetate 105260 855 mmole/min/liter 
ATP requirement for growth 101981 1.21 *10^10 
Bacterial cells in human colon 112982 10^14 
Bacterial cells in human small intestine 105711 10^8 / mL 
Concentration of IPA in serum PMID 29168502 ~10 µM 
Concentration of TMAO in serum PMID 31831639 ~10 µM 
DEBS kcat PMID 8652546 0.05 /s 
Diffusion constant of glucose 104089 0.6 * 105 µm2/s 
Dry weight of E. coli cell 103904 280 fg 
Glucose uptake rate of E. coli 109376 12.83 g/g CDW/h 
Kcat of metabolic enzymes 111415 <100 /s 
Length of E. coli cell 100001 ~2 µm 
Protein copy number per cell 110443 max. ~10^5 
Rate of acetate production PMID 26516911 100 mmol / 12 hours 
Size of small intestine 111127 1.5 L 
Time required for diffusion of 0.1 mm 115474 5 seconds 
Total blood volume of human 101707 5.5 L 
Volume of E. coli cell 114924 1.46 fL 
Volume of human large intestine 111759 ~2 L 
Volume of human small intestine 111127 ~1 L 
 





Figure 2.1. Graphical depiction of theoretical colonic concentrations of bacterial 
metabolites as a function of bacterial abundance. 
The grey shaded area depicts theoretically unattainable concentrations. The blue shaded 
area represents metabolic byproducts, bounded by the theoretical production rates of 
central and secondary metabolites at the top and bottom, respectively. The red line depicts 
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Abstract 
Autoantibodies that recognize extracellular protein epitopes (the “exoproteome”) exert 
potent functional effects that underlie numerous disease processes. Identifying these 
antibodies can thus provide insights into the pathophysiology of a wide spectrum of 
illnesses and therapeutic strategies to treat them. Here, we developed Rapid Extracellular 
Antigen Profiling (REAP) as a technique for comprehensive and high-throughput 
discovery of exoproteome-targeting autoantibodies. With REAP, patient samples are 
applied to a genetically-barcoded library containing 2,688 unique members of the human 
exoproteome displayed on the surface of yeast. Antibody-coated cells are isolated by 
magnetic selection and deep sequencing of their barcodes is used to identify the displayed 
antigens, thereby converting an antibody:antigen binding event into a digital sequencing 
readout. To benchmark the performance of REAP, we screened 77 patients with the rare 
 70 
monogenic autoimmune disease autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy (APECED). REAP sensitively and specifically detected known autoantibody 
reactivities in APECED, including responses against type I interferons, IL-17, IL-22, and 
gastric intrinsic factor. REAP also identified highly prevalent reactivities that had not been 
previously described such as those against the glycoprotein hormone GPHB5. We 
additionally screened 106 patients with systemic lupus erythematosus (SLE) and identified 
novel autoantibody reactivities against a diverse set of antigens including growth factors, 
extracellular matrix components, cytokines, and immunomodulatory proteins. Several of 
these responses were associated with disease severity and specific clinical manifestations 
of SLE, including autoantibodies that target immunoreceptors, antagonize the pro-
inflammatory cytokine IL-33, and recognize endosialin (CD248) and the chemokine 
CCL8. In summary, these findings demonstrate the utility of REAP to atlas the expansive 
landscape of exoproteome-targeting autoantibodies in patients. 
  
Introduction 
Autoantibodies play a major etiological role across a wide range of diseases spanning 
autoimmunity, cancer, metabolic dysfunction, cardiovascular disease, infectious diseases, 
and even neurological and neurodegenerative conditions1–8. Though autoantibodies are 
commonly associated with adverse effects, they can also exhibit disease-ameliorating 
functions that are beneficial to patients. For example, immunosuppressive anti-cytokine 
autoantibodies are associated with less severe disease in numerous autoimmune 
conditions9,10; similarly, anti-tumor specific and opsonizing antibodies are associated with 
better survival in cancer patients11–13. Thus, analogous to genetic mutations, autoantibodies 
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may explain a significant fraction of the clinical and phenotypic variation seen between 
individuals. Discovery of novel functional autoantibody responses in patients therefore has 
the potential to uncover key etiologic factors and therapeutic targets similar to the study of 
human genetics. 
  
Within the human proteome, a particularly important group of autoantibody targets are 
extracellular and secreted proteins (collectively, the “exoproteome”). Because antibodies 
are themselves large (150 kDa) secreted proteins, they are most likely to recognize and act 
upon targets that reside within the same extracellular compartment14. While state-of-the-
art technologies such as protein/peptide microarrays, proteome-scanning libraries using 
phage (PhIP-seq) and bacterial display have enabled the discovery of novel autoantibodies 
in a variety of diseases15–23, these systems have limited sensitivity to detect autoantibodies 
against extracellular targets. This is due in part to the inherent difficulty of working with 
extracellular proteins, which often have unique folding requirements that include signal 
peptide removal, disulfide bond formation, and post-translational modifications such as 
glycosylation. Many of these features are not captured by platforms that express proteins 
or peptides in prokaryotic systems. Similarly, technologies that rely on the use of peptide 
fragments are not able to detect autoantibodies that recognize “conformational” protein 
epitopes (i.e., three dimensional epitopes present when a protein is folded into its native 
state). This limitation may significantly hamper autoantibody detection, since as many as 
90% of antibodies recognize conformational epitopes as opposed to linear peptides24. 
  
Here, we describe Rapid Exoproteome Antigen Profiling (REAP), a new method to 
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discover functional antibodies against the exoproteome. REAP leverages yeast-display 
technology to assess the presence of autoantibody responses to 2,688 extracellular proteins 
present in patient serum or plasma samples through a next-generation sequencing-based 
approach. We use REAP to screen a cohort of 77 APECED patients and successfully 
identify known autoantibodies along with novel “public” (present in many patients) and 
“private” (present in only a few patients) reactivities. We further apply REAP to a cohort 
of 106 patients with SLE and identify autoantibodies targeting cytokines, cytokine 
receptors, growth factors, extracellular matrix components, and immunomodulatory cell 
surface proteins, and validate several of these reactivities through orthogonal assays. In 
both SLE and APECED, we identify autoantibody responses that are associated with 
disease severity and specific clinical disease manifestations. Finally, we find that 
autoantibodies in SLE patients that target the co-inhibitory ligand PD-L2 and the cytokine 
IL-33 have functional antagonist activity ex vivo. These results indicate that REAP is 
broadly useful for the discovery of autoantibodies targeting the exoproteome and that 
functional autoantibodies within patient populations may provide key insights into disease 
pathogenesis and therapeutic approaches. 
  
Results 
Development of Rapid Exoproteome Antigen Profiling 
To develop a system capable of detecting autoantibody responses against conformational 
extracellular proteins, we elected to use yeast surface display to comprehensively sample 
the human exoproteome. As eukaryotic cells, yeast contain several features that enable 
them to express extracellular proteins, including endoplasmic reticulum chaperones, 
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glycosylation machinery, and disulfide bond proofreading systems25. Accordingly, a 
diverse range of mammalian extracellular protein families have been successfully 
expressed with yeast display, including proteins with folds such as the immunoglobulin 
superfamily (IgSF), TNF superfamily (TNFSF), TNF receptor superfamily (TNFRSF), von 
Willebrand factor A (vWFA) domains, fibronectin domain, leucine-rich repeat (LRR), 
EGF-like, insulin-like, cytokines, growth factors, and even complicated assemblies like 
peptide:MHC complexes, T cell receptors, and intact antibodies26–41. We therefore 
constructed a genetically-barcoded yeast-displayed exoproteome library of approximately 
2,700 human extracellular and secreted proteins. The library comprises actively displayed 
proteins from a wide range of protein families and encompasses 87% of all human 
exoproteins with extracellular regions from 50-600 amino acids in length (Fig. 3.1a, 
Supplementary Fig. 3.1a-c). While there is within-library heterogeneity in individual 
protein abundance and the number of unique barcodes associated with each gene, the 
library is relatively uniform and the vast majority of proteins fall within a narrow range 
suited to coverage by standard next-generation sequencing approaches (Fig. 3.1b,c). Full 
details on the design and composition of the library are described in the Methods and in 
Supplemental Table 1. 
  
We next optimized procedures for high-throughput identification of seroreactivities against 
proteins in our exoproteome library for REAP (Fig. 3.1d). Briefly, IgG purified from 
patient serum or plasma is incubated with the yeast library. Autoantibody-coated cells are 
then isolated by magnetic separation and deep sequencing of the library-encoded DNA 
barcodes is used to identify the corresponding antigens encoded by these cells. To quantify 
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the degree of antibody reactivity to a given antigen, we developed a custom scoring 
algorithm (“REAP Score”) based on the enrichment of each antigen’s barcodes after 
selection (see Methods). Screening of the exoproteome library with a set of nine 
conformation-specific monoclonal antibodies against a variety of extracellular proteins 
showed that all antibody targets were detected specifically and robustly (Fig. 3.1e,f). To 
further assess the conformational nature of proteins displayed in the library, we performed 
a REAP screen using a panel of 30 recombinant proteins with known binding partners in 
the library. REAP accurately detected the cognate binding partners for each of these 
proteins, with minimal enrichment of off-target proteins (Fig. 3.1g). 
  
Evaluation of REAP performance in APECED 
To evaluate the capacity of REAP to detect exoproteome-directed autoantibodies in 
complex patient samples such as polyclonal responses in serum, we screened a cohort of 
77 APECED patients (Supplementary Table 2). APECED, also known as autoimmune 
polyglandular syndrome type-1 (APS-1), is a rare genetic autoimmune disease caused by 
mutations in the autoimmune regulator (AIRE) gene, resulting in loss of central tolerance 
and the development of chronic mucocutaneous candidiasis (CMC), severe 
endocrinopathies and other nonendocrine autoimmune sequelae such as pneumonitis, 
hepatitis, alopecia, vitiligo, and vitamin B12 deficiency/pernicious anemia42. Interestingly, 
APECED patients harbor widespread and pathognomonic autoantibodies targeting 
numerous cytokines including type I and type III interferons, IL-22, IL-17A, and IL-17F43–
47. REAP readily identified autoantibody responses against these cytokines in APECED 
patient samples, but not in samples from healthy controls (Fig. 3.2a). Furthermore, the 
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frequencies of these autoreactivities in APECED patients closely matched the frequencies 
determined from previous reports using gold-standard methodologies such as enzyme-
linked immunosorbent assay (ELISA) and luciferase immunoprecipitation system 
immunoassay (LIPS) (Fig. 3.2b)18,43,47. We also identified autoantibodies against gastric 
intrinsic factor (GIF), lipocalin-1 (LCN1), IL-5, IL-6, protein disulfide-isomerase-like 
protein of the testis (PDILT), and BPI fold containing family member 1 and 2 (BPIFA1/2), 
which have been previously described in APECED18–21,48. With respect to GIF reactivities, 
the results seen with REAP demonstrated strong concordance with anti-GIF ELISA results 
from the same patients (Fig. 3.2c). 
  
To investigate the reproducibility of REAP, we compared log2[fold enrichment] between 
technical (intra-assay) replicates across all APECED patient samples and found strong 
positive correlations between replicates (median R2 = 0.914; Supplementary Fig. 1d). To 
investigate the sensitivity of REAP, we titrated varying amounts of IgG and performed 
REAP and ELISA side-by-side for four autoantigens (Supplementary Fig. 1e,f). In each 
case, REAP exhibited higher sensitivity than ELISA by 1-2 orders of magnitude, as seen 
by the calculated EC50 values (Fig. 3.2d). Taken in aggregate, these data indicate that 
REAP is capable of detecting known autoantibody responses against extracellular proteins 
with high sensitivity and precision. 
  
APECED patients exhibit broad exoproteome-targeting autoantibody reactivities 
Previous reports using protein microarrays and PhIP-seq have shown that APECED 
patients have greatly elevated numbers of autoantibody reactivities at a proteome-scale 
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compared to healthy controls. Analyzing the REAP data, we found that global 
autoreactivity present in APECED also extends to the exoproteome (Fig. 3.2e, 
Supplementary Fig. 2a). While some of the reactivities we observed have been previously 
characterized, the screen also uncovered numerous previously undescribed “public” 
(present in more than one patient) and “private” (present in only one patient) reactivities. 
Two notable public reactivities were those against glycoprotein hormone beta-5 (GPHB5), 
a thyrostimulin subunit, and pancreatic triacylglycerol lipase (PNLIP), a tissue-restricted 
antigen that is regulated by Aire in the thymus49. Using ELISA, we confirmed the presence 
of autoantibody responses against these proteins and found that the titers of autoantibodies 
were high, ranging from EC50s of approximately 1:100 to 1:10,000 (Fig. 3.2f,g). We 
additionally were able to correlate particular serological responses to specific, variable 
clinical features of APECED. For example, we found that autoantibodies against lipocalin-
1 (LCN1) and BPIFA1, which had previously been identified in APECED patients with 
Sjogren’s-like syndrome48, were enriched in a subset of APECED patients with 
pneumonitis (6 out of 28 with pneumonitis), a life-threatening non-endocrine complication 
of APECED, but universally negative in 49 patients without pneumonitis or healthy 
controls (Fig. 3.2h). Of note, BPIFA1 reactivity was detected in a patient with biopsy-
proven pneumonitis without reactivity to the known lung-targeted autoantibodies KCNRG 
and BPIFB1, which have an overall sensitivity of ~75% but are negative in a quarter of 
patients with biopsy-proven pneumonitis50. Interestingly, the single patient in our cohort 
with exocrine pancreatic insufficiency, a rare manifestation of APECED42, uniquely 
harbored reactivity to colipase (CLPS), an essential cofactor for pancreatic lipase and 
related lipases (Fig. 3.2a)51. Thus, REAP enabled the detection of novel autoantibody 
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reactivities in the monogenic disease APECED, as well as correlations of autoantibodies 
with clinical features of the disease. 
  
REAP identifies previously undescribed autoantibody reactivities in SLE patients 
We sought to apply REAP to study SLE, a systemic polygenic autoimmune disease 
characterized by loss of tolerance to nucleic acids52. Though autoantibodies are a defining 
feature in SLE, particularly those against nucleic acids and nuclear protein complexes53, 
the role of functional autoantibodies that target the exoproteome is less well established. 
We thus performed REAP analysis on samples from a cohort of 106 SLE patients and 20 
healthy controls. Patient and control demographics are shown in Supplementary Table 3. 
Compared to APECED, we found that exoproteome-targeting autoantibodies in SLE 
patients were strikingly heterogeneous; though a wide variety of autoantigens were 
identified, there were essentially no public autoantigens and most reactivities were present 
in only a few patients (Fig. 3.3a). Several reactivities identified by REAP included 
autoantigens that have previously been described in SLE such as IL-6, type I interferons, 
IL-1α, and TNFα (including identification of a therapeutic anti-TNF antibody administered 
to one of the patients). We further identified numerous novel autoantibodies targeting other 
cytokines (e.g., IL-4, IL-33), chemokines (e.g., CXCL3, CCL8), growth factors (e.g., 
VEGF-B, FGF-21), extracellular matrix components (e.g., epiphycan, vitrin), and 
immunoregulatory cell surface proteins (e.g., FAS, PD-L2, B7-H4). 
  
To validate the large number of candidate autoantibody reactivities identified by REAP, 
we tested autoantibody reactivities against several different proteins using LIPS and ELISA 
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and subsequently confirmed 16 of these autoantigens (Table 1, Fig. 3.3f,i, Supplementary 
Fig. 3a-h, j, n-r). The subset of confirmed autoantibody reactivities consisted of both 
shared and private reactivities and included examples of potentially pathological and well 
as immunomodulatory reactivities, such as those against the extracellular matrix 
component epiphycan (Supplementary Fig. 3n), the cytokine receptor IL-18Rβ 
(Supplementary Fig. 3p), the death receptor FAS/TNFRSF6 (Supplementary Fig. 3e), 
the co-inhibitory ligand PD-L2 (Fig. 3.3f), and the IL-1 family cytokine IL-33 (Fig. 3.3i). 
We additionally characterized the titers and IgG isotypes for several of these responses, 
finding that they spanned a wide range of titers (1:10 to >1:10,000) and isotype classes 
(Supplementary Fig. 3n-r, t-v). Using these results, as well as orthogonal validations of 
known APECED reactivities (Supplementary Fig. 3i-m), we performed receiver 
operating characteristic (ROC) analysis to quantify the performance of the REAP scoring 
algorithm. We found that REAP score sensitively and specifically predicted autoantibody 
reactivity by ELISA and/or LIPS, with an area under the curve (AUC) of 0.892 
(Supplementary Fig. 3s). Because REAP exhibits greater sensitivity for some antigens 
than the ELISA/LIPS “gold standards” (as was the case for type I IFN autoantibodies in 
APECED), this number may represent a conservative estimate of the true performance of 
REAP in predicting autoantibody reactivity. 
  
Exoproteome-targeting autoantibodies in SLE are functional and correlate with 
disease severity 
Given the broad distribution of autoantibody responses in SLE, we wondered if particular 
responses or patterns of reactivity were associated with specific clinical features of the 
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disease. At a global level, we found that the total numbers of autoantibody reactivities 
identified with REAP correlated with worse clinical severity, as measured by the Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI) score54. In particular, we found 
that samples from patients with severe disease (SLEDAI score ≥ 9) had significantly 
increased numbers of autoantibodies compared to healthy controls (Fig. 3.3b, 
Supplementary Fig. 2b). Furthermore, SLE patients in all severity groups had reactivities 
that were not observed in healthy individuals and these patterns of reactivity were 
associated with particular SLE disease phenotypes. For instance, we found that 
autoantibody reactivities against the chemokine CCL8, the cytokine IFN-alpha-6, and the 
C-type lectin CD248 (endosialin) were significantly associated with hematuria and that 
VEGF-B reactivities were associated with leukopenia (Fig. 3.3c). Additionally, patients 
positive for CCL8 reactivity had significantly higher SLEDAI scores, indicating more 
severe disease (Fig. 3.3d). By contrast, patients who exhibited autoreactivity against a set 
of immunoregulatory proteins (PD-L2, RAET1E, CD44, B7H4, BTNL8, CD300E, IER3, 
TNFRSF6, CD300LG, LILRB2, IGLL1, and LILRB4) had significantly lower SLEDAI 
scores compared to patients negative for these autoantibodies (Fig. 3.3e). 
  
Finally, we characterized the functionality of autoantibodies against two novel 
autoantigens identified by REAP, PD-L2 and IL-33. As the primary biological function of 
PD-L2 is mediated by its binding to its receptor PD-1, we tested whether autoantibodies 
against PD-L2 could block this interaction. Serum samples from an SLE patient with anti-
PD-L2 autoantibodies were present at titers >1:100 and inhibited the interaction between 
PD-L2 and PD-1 in a dose-dependent manner, while serum from a control patient without 
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anti-PD-L2 autoantibodies did not (Fig. 3.3f-h). To test the functional effects of anti-IL-
33 autoantibodies, we used the HEK-Blue IL-33 reporter cell line, which produces secreted 
alkaline phosphatase downstream of an NFκB promoter that is activated by the IL-33 
pathway. Bulk IgG (isolated via protein G) from the SLE patient harboring anti-IL-33 
autoantibodies potently neutralized IL-33 signaling with an IC50 less than 0.01 mg/mL, 
while IgG from a control patient without anti-IL-33 autoantibodies had no neutralizing 
effect (Fig. 3.3i-k). These findings underscore the ability of REAP to discover novel 
autoantibodies with functional biological effects. 
  
Discussion 
In the present study we show that REAP is a sensitive and high-throughput platform for 
discovery of exoproteome-directed autoantibodies. By querying antigens in a 
conformationally-active state, REAP enables identification of autoantibodies that are 
difficult to detect, if not entirely invisible to other technologies. This was particularly 
evident in our screen of APECED samples, as we found that REAP was considerably more 
accurate in detecting a well-defined subset of known extracellular autoantigen reactivities 
compared to protein arrays and phage-peptide display approaches. Furthermore, REAP 
enabled the identification of numerous previously undescribed autoantigens in APECED 
patients, a surprising finding given how extensively autoantibodies have been studied in 
this patient population. 
  
We also identified a large set of previously undescribed autoantibody reactivities against 
the exoproteome in SLE patients, a considerably more heterogeneous population than 
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APECED. The vast majority of these novel autoreactivities were relatively private with a 
prevalence of <5% and in some cases present in only a single patient. Though these 
autoantibody responses are rare, our studies suggest that they can exert large biological 
effects that could meaningfully impact disease progression, akin to the effect of rare genetic 
variants. For example, we identified a single SLE patient with very mild disease (SLEDAI 
score of 1) who had extraordinarily high-titer autoantibodies against IL-33 that potently 
neutralized IL-33 signaling in vitro. This suggests that these IL-33 antibodies may have 
played a protective role that ameliorated the severity of the disease in this individual and, 
by extension, that IL-33 blockade could represent a potential therapeutic strategy in SLE. 
Indeed, circulating IL-33 concentrations are elevated in SLE patients and are positively 
correlated with C-reactive protein concentrations and clinical manifestations such as 
thrombocytopenia and erythrocytopenia55,56. Similarly, preclinical studies in mouse models 
have demonstrated that IL-33 exposure is associated with autoantibody production and that 
neutralization of IL-33 suppresses lupus-like disease57,58. Beyond IL-33, we also found that 
SLE patients with autoreactivity against a set of immunoreceptors had substantially lower 
disease severity, indicating that disruption of those pathways and/or opsonization of cells 
that express the receptors could similarly exert a protective effect. Future investigation is 
warranted to determine the prevalence of these autoantibodies in SLE patients and their 
potential protective effects on a larger, confirmatory cohort. Nevertheless, our finding that 
functional autoantibodies responses are highly variable between patients underscores the 
need for technologies like REAP that can provide comprehensive, unbiased antibody 
profiling for large numbers of patients. Without sufficient sample throughput and 
representation of the exoproteome, these rare, but impactful autoantibody responses might 
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not be readily detected. 
  
REAP does have important limitations. While our data indicate that most exoproteome 
antigens are displayed on the surface of yeast and we additionally demonstrated that dozens 
of the library members are biochemically active (via recapitulating known binding 
interactions), not all members of the exoproteome can be expressed in the yeast system. 
This may be due to lack of specific chaperones, expression partners, or post-translational 
modifications required for protein folding and activity. Furthermore, while yeast do 
perform O- and N- linked glycosylation, their glycosylation patterns are characterized by 
a hypermannose structure that is highly divergent from glycosylation seen in humans59. 
Thus, autoantibodies recognizing specific glycoforms of their antigens would not be 
detected with REAP. Further improvement in the REAP platform could therefore involve 
yeast strain engineering to co-express mammalian chaperone proteins to enhance folding 
of human antigens and glycosylation enzymes to produce more human-like glycosylation 
patterns, as has been described for the yeast species Pichia pastoris60. 
  
Though we initially applied REAP to the study of autoimmune conditions, an intriguing 
avenue of future study with REAP and other serological profiling technologies is to 
characterize autoantibody responses in diseases such as cancer, infectious diseases, and 
neurological conditions that are not considered to have a primarily autoimmune etiology. 
Identification of disease-modifying antibody responses in such conditions could implicate 
new molecular pathways that contribute to disease pathology as well as novel therapeutic 
targets and molecular diagnostics. Furthermore, patient autoantibodies could represent 
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potential therapeutic agents themselves. Technologies such as REAP can enable these 
discoveries by revealing the diverse landscape of functional autoantibody responses that 
influence health and disease. 
  
Materials and Methods 
Library production. 
Library design. An initial library of 3093 human extracellular proteins was assembled 
based on protein domains, immunological functions, and yeast-display compatibility. The 
extracellular portion of each protein was identified by manual inspection of topological 
domains annotated in the SwissProt database (January 2018). For proteins with uncertain 
topology, full sequences were run through SignalP 4, Topcons, and GPIPred to identify 
most likely topologies. For proteins with multiple extracellular portions, in general the 
longest individual region was chosen for initial amplification. cDNAs for chosen proteins 
were purchased from GE Dharmacon or DNASU. The protein sequences were further 
modified to match isoforms available in purchased cDNAs. An inventory of antigens 
included in the library are compiled in supplementary table 1 (available at 
https://www.biorxiv.org/content/10.1101/2021.02.11.430703v1.supplementary-material). 
  
Library construction. A two-step PCR process was used to amplify cDNAs for cloning into 
a barcoded yeast-display vector. cDNAs were amplified with gene-specific primers, with 
the forward primer containing a 5’ sequence (CTGTTATTGCTAGCGTTTTAGCA) and 
the reverse primer containing a 5’ sequence (GCCACCAGAAGCGGCCGC) for template 
addition in the second step of PCR. PCR reactions were conducted using 1 µL pooled 
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cDNA, gene-specific primers, and the following PCR settings: 98 ⁰C denaturation, 58 ⁰C 
annealing, 72 ⁰C extension, 35 rounds of amplification. 1 µL of PCR product was used for 
direct amplification by common primers Aga2FOR and 159REV, and the following PCR 
settings: 98 ⁰C denaturation, 58 ⁰C annealing, 72 ⁰C extension, 35 rounds of amplification. 
PCR product was purified using magnetic PCR purification beads (AvanBio). 90 µL beads 
were added to the PCR product and supernatant was removed. Beads were washed twice 
with 200 µL 70% ethanol and resuspended in 50 µL water to elute PCR products from the 
beads. Beads were removed from purified PCR products. The 15bp barcode fragment was 
constructed by overlap PCR. 4 primers (bc1, bc2, bc3, bc4; sequences listed below) were 
mixed in equimolar ratios and used as a template for a PCR reaction using the following 
PCR settings: 98 ⁰C denaturation, 55 ⁰C annealing, 72 ⁰C extension, 35 rounds of 
amplification. Purified product was reamplified with the first and fourth primer using 
identical PCR conditions. PCR products were run on 2% agarose gels and purified by gel 
extraction (Qiagen). Purified barcode and gene products were combined with linearized 
yeast-display vector (pDD003 digested with EcoRI and BamHI) and electroporated into 
JAR300 yeast using a 96-well electroporator (BTX Harvard Apparatus) using the following 
electroporation conditions: Square wave, 500 V, 5 ms pulse, 2 mm gap. Yeast were 
immediately recovered into 1 mL liquid synthetic dextrose medium lacking uracil (SDO -
Ura) in 96-well deep well blocks and grown overnight at 30°C. Yeast were passaged once 
by 1:10 dilution in SDO-Ura, then frozen as glycerol stocks. To construct the final library, 
2.5 µL of all wells were pooled and counted. A limited dilution of 300,000 clones was sub-
sampled and expanded in SDO-Ura. Expression was induced by passaging into synthetic 
galactose medium lacking uracil (SGO-Ura) at a 1:10 dilution and growing at 30°C 
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overnight. 108 yeast were pelleted and resuspended in 1 mL PBE (PBS with 0.5% BSA and 
0.5 mM EDTA) containing 1:100 anti-FLAG PE antibody (BioLegend). Yeast were stained 
at 4° for 75 minutes, then washed twice with 1 mL PBE and sorted for FLAG display on a 
Sony SH800Z cell sorter. Sorted cells were expanded in SDO-Ura supplemented with 35 








Barcode identification. Barcode-gene pairings were identified using a custom Tn5-based 
sequence approach. Tn5 transposase was purified as previously described, using the on-
column assembly method for loading oligos61. DNA was extracted from the yeast library 
using Zymoprep-96 Yeast Plasmid Miniprep kits or Zymoprep Yeast Plasmid Miniprep II 
kits (Zymo Research) according to standard manufacturer protocols. 5 µL of purified 
plasmid DNA was digested with Tn5 in a 20 µL total reaction as previously described. 2 
µL of digested DNA was amplified using primers index1 and index2, using the following 
PCR settings: 98 ⁰C denaturation, 56 ⁰C annealing, 72 ⁰C extension, 25 rounds of 
amplification. The product was run on a 2% gel and purified by gel extraction (Qiagen). 
Purified product was amplified using primers index3 and index4, using the following PCR 
settings: 98 ⁰C denaturation, 60 ⁰C annealing, 72 ⁰C extension, 25 rounds of amplification. 
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In parallel, the barcode region alone was amplified using primers index1 and index5, using 
the following PCR settings: 98 ⁰C denaturation, 56 ⁰C annealing, 72 ⁰C extension, 25 
rounds of amplification. The product was run on a 2% gel and purified by gel extraction 
(Qiagen). Purified product was amplified using primers index3 and index6, using the 
following PCR settings: 98 ⁰C denaturation, 60 ⁰C annealing, 72 ⁰C extension, 20 rounds 
of amplification. Both barcode and digested fragment products were run on a 2% gel and 
purified by gel extraction (Qiagen). NGS library was sequenced using an Illumina MiSeq 
and Illumina v3 MiSeq Reagent Kits with 150 base pair single-end sequencing according 
to standard manufacturer protocols. Gene-barcode pairings were identified using custom 
code. Briefly, from each read, the barcode sequence was extracted based on the 
identification of the flanking constant vector backbone sequences, and the first 25 bp of 
sequence immediately following the constant vector backbone-derived signal peptide were 
extracted and mapped to a gene identity based on the first 25 bp of all amplified cDNA 
constructs. The number of times each barcode was paired with an identified gene was 
calculated. Barcode-gene pairings that were identified more than twice, with an overall 
observed barcode frequency of greater than .0002% were compiled. For barcodes with 
multiple gene pairings matching the above criteria, the best-fit gene was manually 
identified by inspection of all barcode-gene pairing frequencies and, in general, 
identification of the most abundant gene pairing. In the final library, 2,688 genes were 
confidently mapped to 35,835 barcodes. 
  
Rapid Extracellular Antigen Profiling.  
Antibody purification and yeast adsorption. 20 µL protein G magnetic resin (Lytic 
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Solutions) was washed twice with 100 µL sterile PBS, resuspended in 50 µL PBS, and 
added to 50 µL serum or plasma. Serum-resin mixture was incubated for three hours at 4 
⁰C with shaking. Resin was washed five times with 200 µL PBS, resuspended in 90 µL 100 
mM glycine pH 2.7, and incubated for five minutes at room temperature. Supernatant was 
extracted and added to 10 µL sterile 1M Tris pH 8.0 (purified IgG). Empty vector 
(pDD003) yeast were expanded in SDO-Ura at 30 ⁰C. One day later, yeast were induced 
by 1:10 dilution in SGO-Ura for 24 hours. 108 induced yeast were washed twice with 200 
µL PBE (PBS with 0.5% BSA and 0.5 mM EDTA), resuspended with 100 µL purified IgG, 
and incubated for three hours at 4 ⁰C with shaking. Yeast-IgG mixtures were placed into 
96 well 0.45 um filter plates (Thomas Scientific) and yeast-depleted IgG was eluted into 
sterile 96 well plates by centrifugation at 3000 g for 3 minutes. 
  
Antibody yeast library selections. Transformed yeast were expanded in SDO-Ura at 30 ⁰C. 
One day later, at an optical density (OD) below 8, yeast were induced by resuspension at 
an OD of 1 in SGO-Ura supplemented with ten percent SDO-Ura and culturing at 30 ⁰C 
for 20 hours. Prior to selection, 400 µL pre-selection library was set aside to allow for 
comparison to post-selection libraries. 108 induced yeast were washed twice with 200 µL 
PBE and added to wells of a sterile 96-well v-bottom microtiter plate. Yeast were 
resuspended in 100 µL PBE containing appropriate antibody concentration and incubated 
with shaking for 1 hour at 4 ⁰C. Unless otherwise indicated, 10 μg antibody per well was 
used for human serum or plasma derived antibodies and 1 μg antibody was used for 
monoclonal antibodies. Yeast were washed twice with 200 µL PBE, resuspended in 100 
µL PBE with a 1:100 dilution of biotin anti-human IgG Fc antibody (clone HP6017, 
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BioLegend) for human serum or plasma derived antibodies or a 1:25 dilution of biotin goat 
anti-rat or anti-mouse IgG antibody (A16088, Thermo Fisher Scientific; A18869, Thermo 
Fisher Scientific) for monoclonal antibodies. Yeast-antibody mixtures were incubated with 
shaking for 30 minutes at 4 ⁰C. Yeast were washed twice with 200 µL PBE, resuspended 
in 100 µL PBE with a 1:20 dilution of Streptavidin MicroBeads (Miltenyi Biotec), and 
incubated with shaking for 30 minutes at 4 ⁰C. Yeast were then pelleted and kept on ice. 
Multi-96 Columns (Miltenyi Biotec) were placed into a MultiMACS M96 Separator 
(Miltenyi Biotec) and the separator was placed into positive selection mode. All following 
steps were carried out at room temperature. Columns were equilibrated with 400 µL 70% 
ethanol followed by 700 µL degassed PBE. Yeast were resuspended in 200 µL degassed 
PBE and placed into the columns. After the mixture had completely passed through, 
columns were washed three times with 700 µL degassed PBE. To elute the selected yeast, 
columns were removed from the separator and placed over 96-well deep well plates. 700 
µL degassed PBE was added to each well of the column and the column and deep well 
plate were spun at 50 g for 30 seconds. This process was repeated 3 times. Selected yeast 
were pelleted, and recovered in 1 mL SDO -Ura at 30 ⁰C. 
  
Recombinant protein yeast library selections. All pre-selection and yeast induction steps 
were performed identically as those of the antibody yeast library selections. 108 induced 
yeast were washed twice with 200 µL PBE and added to wells of a sterile 96-well v-bottom 
microtiter plate. Yeast were resuspended in 100 µL PBE containing 75 μL clarified protein 
expression supernatant and incubated with shaking for 1 hour at 4 ⁰C. Yeast were washed 
twice with 200 µL PBE, resuspended in 100 µL PBE with 5 μL μMACS Protein G 
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MicroBeads (Miltenyi Biotec), and incubated with shaking for 30 minutes at 4 ⁰C. 
Selection of yeast using the MultiMACS M96 Separator and subsequent steps were 
performed identically as those of the antibody yeast library selections. 
 
Next generation sequencing library preparation and sequencing. DNA was extracted from 
yeast libraries using Zymoprep-96 Yeast Plasmid Miniprep kits or Zymoprep Yeast 
Plasmid Miniprep II kits (Zymo Research) according to standard manufacturer protocols. 
A first round of PCR was used to amplify a DNA sequence containing the protein display 
barcode on the yeast plasmid. PCR reactions were conducted using 1 µL plasmid DNA, 
159_DIF2 and 159_DIR2 primers (sequences listed below), and the following PCR 
settings: 98 ⁰C denaturation, 58 ⁰C annealing, 72 ⁰C extension, 25 rounds of amplification. 
PCR product was purified using magnetic PCR purification beads (AvanBio). 45 µL beads 
were added to the PCR product and supernatant was removed. Beads were washed twice 
with 100 µL 70% ethanol and resuspended in 25 µL water to elute PCR products from the 
beads. Beads were removed from purified PCR products. A second round of PCR was 
conducted using 1 µL purified PCR product, Nextera i5 and i7 dual-index library primers 
(Illumina), and the following PCR settings: 98 ⁰C denaturation, 58 ⁰C annealing, 72 ⁰C 
extension, 25 rounds of amplification. PCR products were pooled and run on a 1% agarose 
gel. The band corresponding to 257 base pairs was cut out and DNA (NGS library) was 
extracted using a QIAquick Gel Extraction Kit (Qiagen) according to standard 
manufacturer protocols. NGS library was sequenced using an Illumina MiSeq and Illumina 
v3 MiSeq Reagent Kits with 75 base pair single-end sequencing or using an Illumina 
NovaSeq 6000 and Illumina NovaSeq S4 200 cycle kit with 101 base pair paired-end 
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sequencing according to standard manufacturer protocols. A minimum of 50,000 reads per 
sample was collected and the pre-selection library was sampled at ten times greater depth 






Data analysis. REAP scores were calculated as follows. First, barcode counts were 
extracted from raw NGS data using custom codes and counts from technical replicates were 
summed. Next, aggregate and clonal enrichment was calculated using edgeR62 and custom 
codes. For aggregate enrichment, barcode counts across all unique barcodes associated 
with a given protein were summed, library sizes across samples were normalized using 
default edgeR parameters, common and tagwise dispersion were estimated using default 
edgeR parameters, and exact tests comparing each sample to the pre-selection library were 
performed using default edgeR parameters. Aggregate enrichment is thus the log2 fold 
change values from these exact tests with zeroes in the place of negative fold changes. 
Log2 fold change values for clonal enrichment were calculated in an identical manner, but 
barcode counts across all unique barcodes associated with a given protein were not 
summed. Clonal enrichment for a given reactivity was defined as the fraction of clones out 
of total clones that were enriched (log2 fold change ≥ 2). Aggregate ( ) and clonal 
enrichment ( ) for a given protein, a scaling factor ( ) based on the number of unique 
yeast clones (yeast that have a unique DNA barcode) displaying a given protein, and a 
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scaling factor ( ) based on the overall frequency of yeast in the library displaying a given 
protein were used as inputs to calculate the REAP score, which is defined as follows.  
 
 and  are logarithmic scaling factors that progressively penalize the REAP score of 
proteins with low numbers of unique barcodes or low frequencies in the library.  is 
applied to proteins with ≤ 5 unique yeast clones in the library and  is applied to proteins 
with a frequency ≤ 0.0001 in the library.  was implemented to mitigate spurious 
enrichment signals from low frequency proteins, which could occur due to sequencing 
errors or stochasticity in the selection process.  was implemented because the clonal 
enrichment metric is less valid for proteins with low numbers of unique yeast clones, 
decreasing confidence in the validity of the reactivity.  and  are defined as follows 
where  is the number of unique yeast clones for a given protein and  is the log10 




Recombinant protein production. 
REAP recombinant protein production. Proteins were produced as human IgG1 Fc fusions 
to enable binding of secondary antibody and magnetic beads to the produced proteins 
during the REAP process. Sequences encoding the extracellular portions of proteins-of-
interests that were present in the yeast display library were cloned by Gibson assembly into 
a modified pD2610-v12 plasmid (ATUM). Modifications include addition of an H7 signal 
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sequence followed by a (GGGGS)3 linker and a truncated human IgG1 Fc (N297A). 
Protein-of-interest sequences were inserted directly downstream of the H7 leader sequence. 
Protein was produced by transfection into Expi293 cells (Thermo Fisher Scientific) in 96-
well plate format. One day prior to transfection, cells were seeded at a density of 2 million 
cells per mL in Expi293 Expression Medium (Thermo Fisher Scientific). In a 96-well plate, 
0.5 μg plasmid DNA was diluted added to 25 μL Opti-MEM (Thermo Fisher Scientific) 
and mixed gently. In a separate 96-well plate, 1.35 μL ExpiFectamine was added to 25 μL 
Opti-MEM and mixed gently. The ExpiFectamine-Opti-MEM mixture was added to the 
diluted DNA, mixed gently, and incubated for 20 minutes at room temperature. Expi293 
cells were diluted to a density of 2.8 million cells per mL and 500 μL of cells were added 
to each well of a 96-well deep well plate. 50 μL of the DNA-ExpiFectamine-Opti-MEM 
mixture was added to each well. The plate was sealed with Breathe-Easier sealing film 
(Diversified Biotech) and incubated in a humidified tissue culture incubator (37 ⁰C, 8% 
CO2) with shaking at 1,200 rpm so that cells were kept in suspension. 18-20 hours post-
transfection, 25 μL enhancer 2 and 2.5 μL enhancer 1 (Thermo Fisher Scientific) were 
added to each well. 4 days post-transfection, media was clarified by centrifugation at 3000-
4000 g for 5 minutes. Clarified media was used for recombinant protein REAP. 
 
ELISA protein production. Sequences encoding the extracellular portions of proteins-of-
interests that were present in the yeast display library were cloned by Gibson assembly into 
pEZT_Dlux, a modified pEZT-BM vector. The pEZT-BM vector was a gift from Ryan 
Hibbs (Addgene plasmid #74099). Modifications included insertion of an H7 Leader 
Sequence followed by an AviTag (Avidity), HRV 3C site, protein C epitope, and an 8x his 
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tag. Protein-of-interest sequences were inserted directly downstream of the H7 leader 
sequence. Protein was produced by transfection into Expi293 cells (Thermo Fisher 
Scientific) according to standard manufacturer protocols. Transfected cells were 
maintained according to manufacturer protocols. 4 days post-transfection, media was 
clarified by centrifugation at 300 g for 5 minutes. Protein was purified from clarified media 
by nickel-nitrilotriacetic acid (Ni-NTA) chromatography and desalted into HEPES 
buffered saline + 100 mM sodium chloride, pH 7.5. Protein purity was verified by SDS-
PAGE. 
  
Biotinylated protein production. Sequences encoding the extracellular portions of proteins-
of-interests were cloned into pEZT_Dlux as described above. Protein was expressed and 
purified as described above minus desalting. Enzymatic biotinylation with BirA ligase was 
performed and protein was purified by size-exclusion fast protein liquid chromatography 
using a NGC Quest 10 Chromatography System (Bio-Rad). 
  
LIPS protein production. Sequences encoding Lucia luciferase (InvivoGen) fused by a 
GGSG linker to the N-terminus of the protein-of-interest extracellular portion (as defined 
above) were cloned by Gibson assembly into pEZT-BM. Protein was produced by 
transfection into Expi293 cells (Thermo Fisher Scientific) according to standard 
manufacturer protocols. Transfected cells were maintained according to manufacturer 
protocols. 3 days post-transfection, media was clarified by centrifugation at 300 g for 5 
minutes. Clarified media was used in luciferase immunoprecipitation systems assays. 
  
 94 
Enzyme-linked immunosorbent assays (ELISAs). 
200 or 400 ng of purchased or independently produced recombinant protein in 100 µL of 
PBS pH 7.0 was added to 96-well flat bottom Immulon 2HB plates (Thermo Fisher 
Scientific) and placed at 4 ⁰C overnight. Plates were washed once with 225 µL ELISA 
wash buffer (PBS + 0.05% Tween 20) and 150 µL ELISA blocking buffer (PBS + 2% 
Human Serum Albumin) was added to the well. Plates were incubated with shaking for 2 
hours at room temperature. ELISA blocking buffer was removed from the wells and 
appropriate dilutions of sample serum in 100 µL ELISA blocking buffer were added to 
each well. Plates were incubated with shaking for 2 hours at room temperature. Plates were 
washed 6 times with 225 µL ELISA wash buffer and 1:5000 goat anti-human IgG HRP 
(Millipore Sigma) or anti-human IgG isotype specific HRP (Southern Biotech; IgG1: clone 
HP6001, IgG2: clone 31-7-4, IgG3: clone HP6050, IgG4: clone HP6025) in 100 µL ELISA 
blocking buffer was added to the wells. Plates were incubated with shaking for 1 hour at 
room temperature. Plates were washed 6 times with 225 µL ELISA wash buffer. 50 µL 
TMB substrate (BD Biosciences) was added to the wells and plates were incubated for 15 
minutes (pan-IgG ELISAs) or 20 minutes (isotype specific IgG ELISAs) in the dark at 
room temperature. 50 µL 1 M sulfuric acid was added to the wells and absorbance at 450 
nm was measured in a Synergy HTX Multi-Mode Microplate Reader (BioTek). 
  
Luciferase immunoprecipitation systems (LIPS) assays. 
Pierce Protein A/G Ultralink Resin (5 µL; Thermo Fisher Scientific) and 1 µL sample 
serum in 100 µL Buffer A (50 mM Tris, 150 mM NaCl, 0.1% Triton X-100, pH 7.5) was 
added to 96-well opaque Multiscreen HTS 96 HV 0.45 um filter plates (Millipore Sigma). 
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Plates were incubated with shaking at 300 rpm for 1 hour at room temperature. Supernatant 
in wells was removed by centrifugation at 2000 g for 1 minute. Luciferase fusion protein 
(106 RLU) was added to the wells in 100 µL Buffer A. Plates were incubated with shaking 
at 300 rpm for 1 hour at room temperature. Using a vacuum manifold, wells were washed 
8 times with 100 µL Buffer A followed by 2 washes with 100 µL PBS. Remaining 
supernatant in wells was removed by centrifugation at 2000 g for 1 minute. Plates were 
dark adapted for 5 minutes. An autoinjector equipped Synergy HTX Multi-Mode 
Microplate Reader (BioTek) was primed with QUANTI-Luc Gold (InvivoGen). Plates 
were read using the following per well steps: 50 µL QUANTI-Luc Gold injection, 4 second 
delay with shaking, read luminescence with an integration time of 0.1 seconds and a read 
height of 1 mm. 
  
PD-L2 blocking assay. 
A single clone of PD-L2 displaying yeast was isolated from the library and expanded in 
SDO-Ura at 30 ⁰C. Yeast were induced by 1:10 dilution into SGO-Ura and culturing at 30 
⁰C for 24 hours. 105 induced PD-L1 yeast were washed twice with 200 μL PBE and added 
to wells of a 96-well v-bottom microtiter plate. Yeast were resuspended in 25 μL PBE 
containing serial dilutions of sample serum and incubated with shaking for 1 hour at 4 ⁰C. 
PD-1 tetramers were prepared by incubating a 5:1 ratio of biotinylated PD-1 and PE 
streptavidin (BioLegend) for 10 minutes on ice in the dark. Yeast were washed twice with 
200 μL PBE, resuspended in 25 μL PBE containing 10 nM previously prepared PD-1 
tetramers, and incubated with shaking for 1 hour at 4 ⁰C. Yeast were washed twice with 
200 μL PBE and resuspended in 75 μL PBE. PE fluorescent intensity was quantified by 
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flow cytometry using a Sony SA3800 Spectral Cell Analyzer. Percent max binding was 
calculated based on fluorescent PD-1 tetramer binding in the absence of any serum. 
  
IL-33 neutralization assay. 
IL-33 reporter cell line construction. The full-length coding sequence for ST2 was cloned 
by Gibson assembly into the lentiviral transfer plasmid pL-SFFV.Reporter.RFP657.PAC, 
a kind gift from Benjamin Ebert (Addgene plasmid #61395). HEK-293FT cells were 
seeded into a 6-well plate in 2 mL growth media (DMEM with 10% (v/v) FBS, 100 
units/mL penicillin, and 0.1 mg/mL streptomycin) and were incubated at 37°C, 5% CO2. 
Once cells achieved 70-80% confluence approximately one day later, cells were transfected 
using TransIT-LT1 (Mirus Bio) in Opti-MEM media (Life Technologies). TransIT-LT1 
Reagent was pre-warmed to room temperature and vortexed gently. For each well, 0.88 ug 
lentiviral transfer plasmid along with 0.66 ug pSPAX2 (Addgene plasmid #12260) and 
0.44 ug pMD2.G (Addgene plasmid #12259), kind gifts from Didier Trono, were added to 
250 μL Opti-MEM media and mixed gently. TransIT-LT1 reagent (6 μl) was added to the 
DNA mixture, mixed gently, and incubated at room temperature for 15-20 minutes. The 
mixture was added dropwise to different areas of the well. Plates were incubated at 37°C, 
5% CO2; 48hrs later, the virus-containing media was collected and filtered with a 0.45μm 
low protein-binding filter. HEK-Blue IL-18 cells (InvivoGen) were seeded into a 6-well 
plate in 1 mL growth media (DMEM with 10% (v/v) FBS, 100 units/mL penicillin, and 0.1 
mg/mL streptomycin) and 1 mL virus-containing media. Cells were incubated at 37°C, 5% 
CO2 for two days before the media was changed. 
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Reporter cell stimulation and reading. Purified IgG titrations and 2 nM IL-33 were mixed 
in 50 µL assay media (DMEM with 10% (v/v) FBS, 100 units/mL penicillin, and 0.1 
mg/mL streptomycin) and incubated with shaking for 1 hour at room temperature. 
Approximately 50,000 IL-33 reporter cells in 50 µL assay media were added to wells of a 
sterile tissue culture grade flat-bottom 96-well plate. IgG-IL-33 mixtures were added to 
respective wells (1 nM IL-33 final concentration). Plates were incubated at 37°C, 5% CO2 
for 20 hours, then 20 µL media from each well was added to 180 μL room temperature 
QUANTI-Blue Solution (InvivoGen) in a separate flat-bottom 96-well plate and incubated 
at 37°C for 3 hours. Absorbance at 655 nm was measured in a Synergy HTX Multi-Mode 
Microplate Reader (BioTek). Percent max signal was calculated based on signal generated 
by IL-33 in the absence of any serum. 
 
ROC analysis of REAP score performance. 
Orthogonal validation data for the receiver operator curve (ROC) analysis was obtained by 
ELISA, LIPS, or clinical autoantibody tests. For ELISA and LIPS, valid reactivities were 
defined as those 3 standard deviations above the healthy donor average for a given protein 
in each assay. ROC analysis was performed using 247 test pairs across 25 different 




SLE patients. Collection of SLE patient blood samples was approved by the Yale Human 
Research Protection Program Institutional Review Boards (protocol ID 1602017276). All 
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patients met the 2012 SLICC classification criteria for SLE63. Clinical information was 
gathered via retrospective EMR review. Informed consent was obtained from all patients.  
 
APECED patients. Collection of APECED patient blood samples was performed under a 
NIAID IRB-approved prospective natural history study (11-I-0187, NCT01386437). 
Patients underwent a comprehensive clinical evaluation at the NIH Clinical Center 
including a detailed history and physical examination, laboratory and radiologic 
evaluations and consultations by a multidisciplinary team of specialists including 
infectious disease, immunology, genetics, endocrinology, gastroenterology, hepatology, 
pulmonology, dermatology, dental, and ophthalmology, as previously described64. All 
study participants provided written informed consent. 
 
Statistical analysis. 
Statistical details of experiments can be found in the figure legends. All REAP screens and 
experimental assays were performed with technical replicates. Data analysis was 
performed using R, Python, Excel, and GraphPad Prism. Unless otherwise specified, 








All code will be available at GitHub. 
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Figure 1 | REAP development and validation. a, Composition of proteins in the yeast library, categorized by broad protein 
families. Abbreviations are as follows: immunoglobulin superfamily (IgSF), epidermal growth factor (EGF), fibronectin (Fn), 
leucine-rich repeat (LRR), urokinase receptor (UPAR), c-type lectin (CLEC), tetraspanin (TSPAN). The cytokine family consists of 
proteins belonging to tumor necrosis factor, interferon, interleukin, and growth factor protein families. b & c, Distribution of total 
protein frequencies (b) and unique yeast clones per protein in the yeast library (c). Solid lines indicate the median of the distribu-
tion and dotted lines indicate first and third quartiles. d, Simplified schematic of REAP. Antibodies are incubated with a barcoded 
yeast library displaying members of the exoproteome in 96-well microtiter plates. Antibody bound yeast are enriched by magnetic 
column-based sorting and enrichment is quantified by next-generation sequencing. f, Heatmap of results from REAP screen of 9 
monoclonal antibodies. Only relevant monoclonal antibody targets are displayed. e, Representative sample from screen in f. 
Monoclonal antibody target is highlighted in red and labelled. Background subtraction was performed by subtracting the score of a 
selection performed with beads and secondary alone. Scores below the average background level are not shown. g, REAP 
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IFN- 2 97.4 100
IFN- 5 97.4 100
IFN- 6 9 .7 100
IFN- 8 97.4 100
IFN- 13 9 .7 100
IFN- 14 97.4 100
IFN- 17 97.4 100
IFN- 3.1 100
IFN- 2 22.1 2
IFN- 3 19.5 2
IL-22 97.4 9147  94
IL-17A 27.27 35  4147
IL-17F 5 .4 70  7547
IL-5 9.1 16
Figure 2 | REAP screen of APECED patients. A cohort of 77 APECED patients and 20 healthy controls were screened using 
REAP. a, Heatmap of REAP scores. Antigen groups were manually categorized. b,
healthy donor average score plus 3 standard deviations) against 14 antigens based on REAP and prior literature . c, Violin 
plot of GIF REAP scores in APECED samples stratified by intrinsic factor clinical autoantibody test results. d, EC50 of fitted REAP 
and ELISA dose response curves for detection of autoantibodies against four proteins in one APECED patient. See supplementa-
ry figure 1e,f for dose response curves. e, Violin plot of the number of reactivities in APECED and control samples at a score 
cutoff of 3. f, anti-GPHB5 and g, anti-PNLIP pan-IgG ELISAs conducted with serial dilutions of serum. Error bars represent 
standard deviation. h, Heatmap of LCN1 and BPIFA1 REAP scores in APECED samples stratified by pneumonitis positivity. Listed 
p-values represent significance for the association between LCN1 or BPIFA1 REAP positivity and pneumonitis. Significance in c 
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Figure 3 | REAP screen of SLE patients. A cohort of 106 unique SLE patients spanning 155 samples and 20 healthy controls 
was screened using REAP. a, Heatmap of REAP scores where each column is a unique patient. For patients with longitudinal 
samples, the maximum REAP score for each given reactivity is shown. Antigen groups were manually categorized. Patients are 
ordered from left to right by increasing SLEDAI score. White stars symbolize detection of a therapeutic antibody. Score was 
artificially capped at 7 to aid visualization. b, Violin plots of the number of reactivities in SLE samples stratified by disease severity 
and control samples at a score cutoff of 3. Significance was determined using a Kruskal-Wallis test followed by a Dunnett’s test. c, 
Heatmap of false discovery rate-adjusted p-values from two-sided Mann-Whitney U tests comparing REAP score distributions for 
specific proteins between patients stratified by disease manifestations. Only reactivities positive in at least 3 patients were tested. 
d, SLEDAI scores for SLE patients stratified by reactivity against CCL8. e, SLEDAI scores for SLE patients positive or negative by 
REAP score for reactivities against immunoregulatory antigens (defined in a). f, anti-PD-L2 and i, anti-IL-33 pan-IgG ELISAs 
conducted with serial dilutions of SLE or control serum. g, schematic and h, results of PD-L2 blocking assay conducted with serial 
dilutions of serum from a control and the SLE patient in f. j, schematic and k, results of IL-33 neutralization assay conducted with 
serial dilutions of IgG from a control and the SLE patient in i. Significance in d and e was determined using a two-sided 












# Validated   
by ELISA or 
LIPS
VEGF-B 10 1.67 - 8.88 10
IFN- 17 8 1.85 - 10.33 8
IFN- 8 7 1.13 - 8.92 4
FAS 6 1.73 - 4.95 4
EPYC 4 4.93 - 9.46 4
CSPG5 6 1.64 - 5.92 3
IL-6 3 3.60 - 7.82 3
PD-L2 4 2.43 - 9.69 2
IL-4 2 5.78 - 6.09 2
CCL8 4 4.59 - 6.44 1
IL-33 1 3.88 1
IL-18R 1 3.3 1
IL-16 1 4.03 1
LILRB4 1 3.85 1
ACVR2B 1 8.56 1
IER3 1 4.23 1
IFNL2 6 3.27 - 7.74 0
NGFR 4 3.40 - 6.73 0
RGMB 4 4.15 - 5.49 0
CD44 1 6.34 0
RAET1E 1 7.6 0
Table 1
Table 1 | Orthogonal validation of SLE autoantibody 





100 100 100 100 100 100 100 100 94 70 35 28 28 16
99 97 97 99 97 97 99 83 97 58 27 22 20 9
87 71 69 63 58 57 41 45 0 0 18 3
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Supplementary Figure 1 | Exoproteome yeast display library properties. a, Flowchart of steps in identification and annotation 
of extracellular or secreted proteins for inclusion in the library. b, Pie chart of all extracellular or secreted proteins identified in a. 
Proteins were not attempted if they had an ectodomain less than 50 amino acids or less than 600 amino acids. c, Percent of 
proteins displayed in each protein family included in the library. The dotted line represents the aggregate display level in the 
library. Abbreviations are as follows: immunoglobulin superfamily (IgSF), epidermal growth factor (EGF), fibronectin (Fn), 
leucine-rich repeat (LRR), urokinase receptor (UPAR), c-type lectin (CLEC), tetraspanin (TSPAN). The cytokine family consists of 
proteins belonging to tumor necrosis factor, interferon, interleukin, and growth factor protein families. d, Box plot of Log2[fold 
enrichment] R² coefficient of determination values between technical replicates of APECED patients screened in figure 2. e, 
REAP versus f, ELISA dose-response curve comparison for APECED autoantibodies against four proteins. REAP data is from a 
screen conducted using varying concentrations of AIRE.19 IgG. Curves were fit using a sigmoidal 4 parameter logistic curve. For 
REAP, curves were fit based on Log [fold enrichment]. For ELISA, curves were fit based on optical density at 450 nm. Error bars 
represent standard error of the mean. g, Comparison of autoantibody detection frequencies in APECED patient cohorts by REAP, 
LIPS18, ProtoArray18, and PhIP-Seq21. Frequencies are listed as a percentage inside each circle. Size and color of circles are 
proportional to detection frequency. For REAP, detection frequency was calculated as in figure 2b. For LIPS and ProtoArray, 
detection frequencies were provided in the corresponding publication. For PhIP-Seq, detection frequency was calculated based on 
figures in the corresponding publication. For reactivities labelled n.d., either data was not publicly available or the autoantibody 







































































APECED   
(n = 77)
control    
(n = 20)
score  24.03 5.30
score  2 17.12 2.25
score  3 12.95 1.50
score  4 10.69 1.25
score  5 8.73 0.75
score  6 6.29 0.40




severe   
(n = 45)
active    
(n = 33)




control   
(n = 20)
score  8.67 6.67 6.98 6.97 5.30
score  2 5.13 3.52 3.47 3.79 2.25
score  3 3.64 2.30 2.51 2.53 1.50
score  4 2.69 1.67 1.72 1.74 1.25
score  5 1.91 0.91 1.35 1.06 0.75
score  6 1.13 0.45 0.95 0.79 0.40
b
d
Supplementary Figure 2 | APECED and SLE reactivity distributions. a, Violin plots of the number of reactivities in APECED 
and control samples at a score cutoff of 1 or 2. b, Mean number of reactivities in APECED and control samples at various score 
cutoffs, along with indicators of significance. c, Violin plots of the number of reactivities in SLE samples stratified by disease 
severity and control samples at a score cutoff of 1 or 2. d, Mean number of reactivities in SLE samples stratified by disease 
severity and control samples at various score cutoffs. Comparisons were made between each disease severity group and the 
control group. Significance in a and b was calculated using a two-sided Mann-Whitney U test. Significance in c and d was deter-
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Supplementary Figure 3 | REAP validation and ROC analysis. a-l, Single-point ELISAs or LIPS conducted with SLE, 
APECED, or control serum to detect autoantibodies against ACVR2B (a), CCL8 (b), CSPG5 (c), CXCL3 (d), Fas (e), IL-4 (f), IL-6 
(g), IL-16 (h), IL-22 (i j k), and IFNL2 (l). Serum dilutions are listed in the title of each plot. m-r, ELISAs or 
LIPS conducted with serial dilutions of SLE, APECED, or control serum to detect autoantibodies against BPIFA2 (m), EPYC (n), 
IER3 (o), IL18RAP (p), LILRB4 (q), and VEGF-B (r). Dotted lines in a-l represent the control average + 3 standard deviations. s, 
Receiver operating characteristic curve of the ability of REAP score to predict validation of a REAP reactivity in an orthogonal 
assay. A full description of this analysis can be found in the materials and methods section. t, Anti-epiphycan IgG subclass 
specific ELISA conducted with serial dilutions of serum from the SLE patient with highest titers in n. u, Anti-IL-18RAcP subclass 
specific ELISA conducted with serial dilutions of serum from the SLE patient in p. v, Anti-PD-L2 IgG subclass specific ELISAs 
conducted with serial dilutions of serum from the SLE patient in figure 3f. All error bars in this figure all represent standard 







APECED cohort characteristics (n = 77) Number (%) 
Age* 24 (14.4) 
Gender (female)  45 (58) 
Ethnicity
 
White Non-Hispanic 68 (88) 
White/Hispanic 5 (7) 
AIRE alleles** 
 
c.967_979del13 79 (51) 
c.769C>T 21 (14) 
Clinical manifestations 
 
Chronic mucocutaneous candidiasis 66 (86) 
Adrenal insufficiency 62 (81) 
Hypoparathyroidism 63 (82) 
Hypothyroidism 18 (23) 
Hypogonadism  26 (34) 
Autoimmune pneumonitis 28 (36) 
Autoimmune hepatitis 25 (33) 
Intestinal dysfunction 53 (69) 
Exocrine pancreatic insufficiency 1 (1) 
Asplenia 10 (13) 
Alopecia 26 (34) 
Vitiligo 19 (25) 
Sjogren's-like syndrome 30 (39) 
Autoimmune gastritis 30 (39) 
B12 deficiency 20 (26) 
Intrinsic factor antibody  24 (31) 
Lung-targeted autoantibodies*** 
 
BPIFB1 19 (26) 
KCNRG 4 (6) 
*Age is represented as mean (standard deviation) in years 
**The denominator for AIRE mutant alleles is 154 
***Data available for 72 patients 
AIRE, autoimmune regulator; APECED, autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy; BPIFB1, BPI fold containing family B member 1 








Mean (SD) or as indicated SLE Cohort (n = 85*) 
Healthy Controls 
(n = 20) 
Age, (years) 41.7 (12.6) 37.2 (11) 
Gender, N (% female) 76 (89.4) 12 (60) 
Ethnicity, N (%) 
 
 
  Hispanic 22 (26) 3 (15) 
  Non-Hispanic 35 (41) 8 (40) 
  African American 28 (33) 9 (45) 
Clinical Manifestations, N (%)   
  Skin 40 (47.1)  
  Mucocutaneous 16 (18.8)  
  Musculoskeletal 29 (34.1)  
  Renal 20 (23.5)  
  Cardiorespiratory 4 (4.7)  
  Hematological 7 (8.2)  
  Neuropsychiatric 0 (0)  
Serologies, N (%)   
  Positive dsDNA  40 (47.1)  
  Low complement  34 (40)  
SLEDAI score 6.3 (6.1)  
Medications, any use N (%)   
  Prednisone  40 (47.1)  
  Hydroxychloroquine 72 (84.7)  
  Mycophenolate mofetil 24 (28.2)  
  Methotrexate 6 (7.1)  
  Azathioprine 4 (4.7)  
  Belimumab 6 (7.1)  
  Others (cyclophosphamide, 
rituximab, tacrolimus, infliximab, etc.) 
10.6%  
Abbreviations: SLEDAI (Systemic Lupus Erythematosus Disease Activity Index).  
Prednisone dosing ranges from 5 mg daily to 60 mg daily. 
*Complete clinical data was not available for a subset of patients. A total of 106 patients 
were screened. 
Supplementary Table 3 | SLE patient and control demographics and clinical 
characteristics.
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Chapter 4: A host-microbiota interactome atlas reveals extensive transkingdom 
connectivity 
Connor E. Rosen, Nicole Sonnert, Yile Dai, Eric Wang, Jason Bishai, Tyler Rice, Jaime 
Gonzales-Hernandez, Changhui Guan, Agata A. Bielecka, Suzanne Fischer, Julia Oh, 
Aaron M. Ring, Noah W. Palm     
 
ABSTRACT 
The myriad bacteria that live in and on us have diverse impacts on human physiology, yet 
the molecular details underlying host-microbiota interactions remain largely unknown. 
To map the host-microbiota interactome, we developed a novel technology called 
BASEHIT that enables comprehensive evaluation of interactions between an individual 
bacterial strain and thousands of human extracellular proteins. Using BASEHIT, we 
evaluated 1.28 million potential interactions between 477 phylogenetically and 
functionally diverse human-associated bacterial strains and 2,688 human extracellular 
proteins. The resulting host-microbiota interactome atlas contains >3,000 previously 
undiscovered interactions that may contribute to tissue colonization, immunomodulation, 
and strain-specific impacts on human disease. By dramatically expanding the landscape 
of known host-microbiota interactions, this atlas will facilitate molecular dissection of the 






The bacterial microbiota has profound impacts on nearly all aspects of human biology, 
from regulating immunity in the gut to shaping mood and behavior, though the molecular 
bases of these effects remain largely elusive1-4. Recent studies have revealed important 
roles of small-molecule metabolites in influencing host (patho)physiology5-8. By contrast, 
the interactions between the microbiota and host extracellular/secreted proteins (the 
“exoproteome”) remain largely unexplored. This is in spite of the numerous ways that the 
microbiota can potentially interface with the host exoproteome. For example, secreted 
proteins can bind microbes that are separated from the host epithelium by physiochemical 
barriers, and resident microbes that breach these barriers directly contact the host 
epithelial surface and apically expressed proteins9-10. Furthermore, microbial 
translocation beyond the epithelium to local and sometimes even distant tissues has 
recently emerged as a common feature of various pathophysiological states, including 
metabolic syndrome, autoimmunity, cancer, and aging11-13. Thus, indigenous microbes 
have innumerable opportunities to encounter diverse members of the host exoproteome, 
well beyond obvious binding partners at barrier surfaces.  
 
Understanding host exoproteome:microbiota interactions may reveal the mechanisms by 
which indigenous microbes colonize host-associated niches and modulate host responses 
and thereby provide key insights into the role of specific host-associated microbes in 
human health and disease. However, a deeper understanding of direct host-microbe 
interactions has been hampered by a lack of tools for unbiased detection of microbial 
interactions with extracellular host proteins14-16. We thus sought to develop a novel 
method to enable mapping of host-microbiota interactions across the entire human 
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exoproteome and to create a draft “atlas” of host:microbe interactions spanning diverse 
bacterial phylogenies and host tissues. 
 
BASEHIT: a tool to discover bacterial interactions with the host exoproteome 
We developed and optimized a high-throughput technology to screen intact microbial 
cells for the ability to bind human proteins displayed on the surface of yeast, which we 
call BASEHIT (BActerial Selection to Elucidate Host-microbe Interactions in high 
Throughput, Fig. 4.1A). The BASEHIT process involves surface biotinylation of 
bacterial cells, incubation of the labeled bacteria with genetically-barcoded yeast clones 
that display individual human extracellular proteins, isolation of bacteria:yeast 
complexes, and next-generation sequencing of the barcodes encoded by the enriched 
yeast clones. Using these data, we derive a “BASEHIT score” that represents the 
predicted degree of interaction between an individual microbe and a given host protein on 
the basis of the differential enrichment of the protein’s corresponding barcodes after 
selection (see methods).  
 
We first optimized and validated the conditions for protein-dependent, bacteria:yeast 
complex formation and isolation using a gold-standard host-microbe interaction, 
Staphylococcus aureus binding to human IgG Fc17. The BASEHIT process specifically 
enriched Fc-expressing yeast clones by approximately 50-fold from a mixture of GFP-
labeled IgG Fc-expressing yeast and a large excess of yeast expressing irrelevant control 
human proteins (Fig. 4.1B). This result thus confirmed that bacteria:yeast complex 
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formation was strongly dependent on the expression of a relevant host ligand and that the 
magnetic selection process enables robust enrichment. 
 
To enable comprehensive evaluation of potential bacterial binding to the human 
exoproteome, we created a curated, barcoded library of 3,100 human extracellular and 
secreted proteins displayed clonally on the surface of yeast. This library covers over 50% 
of the total human exoproteome and includes a broad range of transmembrane, secreted, 
and membrane-associated proteins with diverse protein folds, expression patterns, and 
biological functions. Because yeast are not capable of expressing all human exoproteins, 
we selected for clones that successfully displayed protein on their surface through 
fluorescence-activated cell sorting (FACS) of FLAG epitope tag (which is only present 
on yeast clones that express full-length proteins). Greater than 86% of proteins (2,688) 
remained in the library after FACS selection, which were present with a roughly flat 
distribution of frequencies and represented by approximately 15 unique barcodes each. 
We thus used this library for interactome mapping in subsequent studies.  
 
To evaluate the potential of BASEHIT to map host:bacterial interactions using this 
library, we assessed the interactome of an adherent-invasive Escherichia coli (AIEC) 
isolate that expresses a Dr-family adhesin and binds to the host cell surface proteins 
CD55 and CEACAM118-19. As a control, we simultaneously profiled several other E. coli 
strains lacking these adhesins. As seen in Fig. 4.1C, BASEHIT accurately identified 
CD55 and CEACAM1 as the top predicted binding partners for AIEC, whereas control E. 
coli strains demonstrated no detectable binding to these proteins (Fig. 4.1D).  
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Discovery and validation of novel host:microbiota interactions using BASEHIT 
We used BASEHIT to map the landscape of host-microbiota interactions for a large 
collection of human-associated bacteria representing diverse phylogenies and 
biogeographical niches. We assembled and screened a collection of 477 bacterial strains 
from the human microbiota isolated from the mouth, gut, lung, skin, vagina, and blood 
that encompassed 6 phyla, 44 families, and 59 genera20-22. This collection also included 
multiple strains from 34 species to evaluate the impact of strain variation on host-
microbiota interactions. In total, we interrogated approximately 1.3 million potential 
binary interactions between individual host proteins and unique bacterial strains and 
identified 2,949 predicted binding events that passed the conservative BASEHIT score 
cutoff of 5 (Fig. 4.2A; see methods for a detailed description of BASEHIT scoring).  
 
The total number of proteins bound by each isolate was highly variable and largely 
independent of phylogeny. Overall, the number of predicted interactions per strain 
spanned two orders of magnitude, from zero detected interactions to over 100 (Fig. 
4.2B). While the majority of strains (348 out of 477, 73%) interacted with 5 or fewer host 
proteins, 16 strains bound to more than 30. These “superbinder” strains were derived 
from diverse tissues and phylogenies. Notably, two superbinder strains from the intestine 
(an Erysipelotrichaceae strain and a Proteus mirabilis strain) have been previously 
shown to cause severe intestinal inflammation in mouse models of inflammatory bowel 




Interaction patterns also varied widely across protein families and folds. For example, 
1,816 (68%) of the 2,688 proteins in the exoprotein library failed to interact significantly 
with any bacterial strains, 362 proteins interacted with only one or two strains, and 18 
proteins (0.7%) interacted with 10 or more strains (Fig. 4.2C). The lack of predicted 
interactions for most proteins was not due to failed expression or aberrant folding of 
those specific proteins as many non-interacting proteins were readily detected in the yeast 
library via staining with specific antibodies (Chapter 3). 
 
Overall, the BASEHIT screen predicted thousands of previously undiscovered molecular-
level host:microbe interactions, dramatically expanding the known universe of potential 
mechanisms through which indigenous microbes interface with and may impact the host. 
These interactions were distributed across diverse phyla (Fig. 4.2D) and tissues of origin 
of the bacteria evaluated. Furthermore, the interactions involved a multitude of host-
protein families with varied cellular localizations and tissue expression patterns. To 
evaluate the predictive value of the BASEHIT screening results, we selected 64 putative 
interactions across a broad distribution of bacterial phylogenies and protein types to 
validate using orthogonal approaches. We validated 49 of these interactions via flow 
cytometry or ELISA (Fig. 4.2E, F), demonstrating that BASEHIT accurately identifies 
novel host-microbe interactions with high confidence. We hypothesize that this may 
represent a conservative estimate of the true predictive value of BASEHIT; indeed, due to 
the high density of expression of receptor:ligand pairs on the yeast and bacterial cell 
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surfaces, BASEHIT may be capable of detecting low-affinity, high-avidity interactions 
that are otherwise too weak to be detected by conventional approaches. 
 
A draft atlas of the host-microbiota interactome 
The BASEHIT process enables facile determination of host-microbe interactome 
“fingerprints” for hundreds of individual bacterial strains. We thus used the 477 unique 
interactomes determined via BASEHIT to assemble an expansive host 
exoproteome:microbiota interactome atlas that surveys the diverse landscape of bacteria 
contained within the collective human microbiota. This interactome atlas facilitated the 
direct comparison of hundreds of host-associated bacterial strains based on patterns of 
interaction with host exoproteins rather than microbial phylogenies. Nonlinear 
dimensionality reduction based on individual strain-specific interactomes revealed 
diverse patterns of interaction across taxa that distributed across several clusters (Fig. 
4.3A). The majority of strains localized to a diffuse central cluster (cluster 1), reflecting 
the relative uniqueness of individual microbial interactomes and a lack of common host 
interaction partners among most strains. However, some discrete interaction patterns also 
emerged in the form of 3 additional clusters, which are characterized by distinct 
modalities of microbial interaction with the host. Specifically, a group of 
Propionibacterium acnes strains formed a unique cluster (cluster 2), a subset of 
Staphylococcus strains (cluster 3), and a mixed-cluster that was dominated by Klebsiella 
strains, but also contained representatives from Actinobacteria, Firmicutes, and 
Fusobacteria (cluster 4).  
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Divergent host protein binding patterns imply functional variation between 
phylogenetically-related bacterial strains 
Bacterial strains assigned to the same species can exhibit divergent impacts on host 
physiology25-27. In principle, strain-specific interactions with the exoproteome could 
contribute to such functional variation. To assess the degree of heterogeneity in host 
protein binding between bacterial strains, we first compared the interactomes of 148 skin-
derived isolates from five common Staphylococcus species. Multiple Staphylococcus 
strains interacted with skin-expressed proteins, including the corneodesmosome proteins 
CDSN and KLK7, junctional proteins CLDN4 and FAT2, and the secreted protein 
SLURP1 (Fig. 4.4A). Among these proteins, CDSN, FAT2, and SLURP1 were uniquely 
recognized by skin-derived Staphylococcus isolates and not by any other strain in the 
BASEHIT atlas. However, exoprotein-binding patterns still varied dramatically both 
within and between Staphylococcus species, and even the most common interactions 
were observed in less than ten percent of all Staphylococcus strains. Importantly, strain 
variation in host-protein binding was not due to technical variation in BASEHIT since 
differential binding was also observed via bacterial flow cytometry.  
 
We next focused on two bacterial taxa from the gut microbiota that are associated with 
distinct human pathologies, the genus Fusobacterium and the species Ruminococcus 
gnavus. Fusobacterium species are enriched in tumors28-30 and specific Fusobacterium 
nucleatum strains modulate host immunity through direct interactions with TIGIT and 
CEACAM131-33. The seventeen Fusobacterium strains in the BASEHIT atlas spanned 
five tissues of origin. However, nearly all Fusobacterium isolates bound to at least one 
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known immunomodulatory host protein, including two ITIM-coupled 
immunosuppressive proteins (SIRPA and LAIR1), four cytokine receptors (IL15RA, 
IL13RA1, IL10RB, and IL9R), and four cytokines (CSF3, IFNB1, IL10, IL33) (Fig. 
4.4B). These interactions further underscore the immunomodulatory potential of this 
genus and provide molecular insights into the potential role of Fusobacterium in 
tumorigenesis and modulation of the immune tumor microenvironment. 
  
R. gnavus is enriched in inflammatory bowel disease (IBD) subjects and strain-level 
variation and “clade switching” in R. gnavus are closely associated with IBD flares34-36. 
Examination of R. gnavus isolates in the BASEHIT atlas revealed strain-variable 
interactions with multiple immunoreceptors expressed on T cells, including CD7, 
TNFRSF1B, TNFRSF4, TNFRSF7, TNFRSF9, and TMEM149, as well as the mucus-
associated trefoil factors TFF1 and TFF2 (Fig. 4.4C). Interestingly, these interactions 
were most evident in isolates derived from IBD patients, which we confirmed for CD7 by 
flow cytometry (Fig. 4.4D). R. gnavus-CD7 interactions were also highly host-specific as 
mouse CD7 failed to bind to human R. gnavus (Fig. 4.4E). These interactions provide 
new insights into the mechanisms by which R. gnavus may modulate immune-mediated 
disease in humans and demonstrate that direct interactions between commensal microbes 
and defined host receptors can exhibit host-species specificity.  
  
Discussion 
Here, we describe a novel technology that enables comprehensive mapping of 
host:bacteria interactomes across hundreds of bacterial strains and the generation of a 
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draft host-microbiota interactome atlas. This atlas describes thousands of previously 
undiscovered connections between indigenous microbes and their human hosts at a 
molecular-level resolution and defines host-interaction “fingerprints” for hundreds of 
human-associated microbes. As expected, the BASEHIT atlas is sparse overall - most 
bacterial strains bound fewer than five host proteins and most exoproteins failed to 
interact with any of the bacterial strains in our collections. However, BASEHIT’s ability 
to comprehensively test millions of potential bacteria:protein binding events revealed a 
remarkable breadth and diversity of transkingdom interactions, which constitute a rich 
but largely unexplored feature of host-microbiota connectivity. 
 
Recent advances in metagenomics have clearly established that strain variation in the 
microbiota can impact human disease outcomes. However, the identification of the key 
distinctions between related strains that explain their differential impacts on host biology 
remains a major challenge. BASEHIT offers an orthogonal and complementary method 
to ascribe functions to individual microbial strains in a phylogenetically unbiased 
manner, using host-exoproteome interactions as a “lens” to predict causal roles for 
microbiota constituents in human health. This feature of BASEHIT may enable 
functional classification of otherwise phylogenetically disparate microbes that exert a 
common effect on the host by interacting with a shared set of host exoproteins. 
Conversely, integration of interactome data with comparative genomics may also enable 
the assignment of novel functions to large numbers of previously unannotated genes in 
the human microbiome that are specialized for mediating direct interactions with the host.   
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MATERIALS AND METHODS 
 
Yeast Library 
The yeast library design, construction, and characterization is described in Chapter 3. 
 
BASEHIT screening. 
Bacterial growth and labeling. Approximately 5 OD units of saturated bacterial culture 
were pelleted and washed 3 times with 1 mL PBS. Washed bacteria were resuspended in 
1 mL PBS with 5 µM Sulfo-NHS-LC-Biotin (Thermo Scientific) and incubated at 37° for 
30 min. Excess unreacted biotinylation reagent was quenched by addition of 10 µL of 1M 
Tris pH 8.0, and cells were washed with 1 mL PBS. Labeled cells were resuspended in 1 
mL PBS with 10% (v/v) glycerol and frozen at -80°C for selections. 
 
Yeast library selections. The yeast library was expanded in SDO-Ura at 30 °C. One day 
later, yeast were induced by resuspension at an OD of 1 in SGO-Ura supplemented with 
ten percent SDO-Ura and culturing at 30 °C for 24 hours. Prior to selection, plasmid 
DNA was extracted from 400 µL of the pre-selection library to allow for comparison to 
post-selection libraries using a Zymoprep Yeast cell Plasmid Miniprep II kit (Zymo 
Research) by standard manufacturer protocols. 107 induced yeast cells were pelleted in 
sterile 96-well v-bottom microtiter plate. Yeast cell were resuspended in 100 µL PBE, 10 
µL of biotinylated bacteria were added, and the yeast were incubated with shaking for 2 
hours at 4 °C. Yeast cells were washed once with 200 µL PBE, resuspended in 100 µL 
PBE with a 1:100 dilution of streptavidin microparticles (Spherotech, 0.29 µm), and 
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incubated with shaking for 1 hour at 4 °C. Yeast cells were washed once with 200 µL 
PBE. Yeast cell were then pelleted and kept on ice. All following steps were carried out 
at room temperature. Yeast cells were resuspended in 150 µL PBE. A custom 96-well 
magnet was used to remove bead-bound yeast, which were washed twice with 150 µL 
PBE by removal and subsequent re-application of the magnet. Washed yeast cells were 
eluted into 150 µL PBE by removal of the magnet. Selected yeast were pelleted, and 
expanded by growth in 1 mL SDO-Ura supplemented with chloramphenicol at 30 °C for 
48 hours. 
 
Next generation sequencing library preparation and sequencing. DNA was extracted 
from yeast libraries using Zymoprep-96 Yeast Plasmid Miniprep kits or Zymoprep Yeast 
Plasmid Miniprep II kits (Zymo Research) according to standard manufacturer protocols. 
A first round of PCR was used to amplify a DNA sequence containing the protein display 
barcode on the yeast plasmid. PCR reactions were conducted using 1 µL plasmid DNA, 
159_DIF2 and 159_DIR2 primers, and the following PCR settings: 98 ⁰C denaturation, 
58 ⁰C annealing, 72 ⁰C extension, 20 rounds of amplification. The PCR product was 
directly used as template for the second round of PCR. A second round of PCR was 
conducted using 1 µL PCR product, Nextera i5 and i7 dual-index library primers 
(Illumina), and the following PCR settings: 98 ⁰C denaturation, 58 ⁰C annealing, 72 ⁰C 
extension, 20 rounds of amplification. PCR products were pooled and run on a 2% 
agarose gel. The band corresponding to 257 base pair was cut out and DNA (NGS 
library) was extracted using a QIAquick Gel Extraction Kit (Qiagen) according to 
standard manufacturer protocols. NGS library was sequenced using an Illumina MiSeq 
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and Illumina v3 MiSeq Reagent Kits with 75 base pair single-end sequencing according 
to standard manufacturer protocols. 
 
Data analysis. Barcode counts were extracted from raw NGS data and analyzed using 
custom codes. Enrichment calculations were performed using edgeR. Briefly, the 
enrichments for all individual barcodes as well as the total abundance of each protein 
(obtained as the sum of all barcode counts associated with that protein) were calculated 
relative to the pre-selection library. The fraction of barcodes associated with a protein 
with a positive enrichment (calculated log2FC >0) was multiplied by the overall 
enrichment for that protein to provide a raw enrichment score. The raw enrichment score 
was normalized by subtracting the raw enrichment scores of beads-only control selected 
wells. All negative values were set to 0. Data generated from screens run on separate 
days were processed separately until this step, to control for variation due to library drift. 
Merged data across experiments were further processed to derive the BASEHIT score. 
The merged, beads-corrected data were z-scored by protein. Proteins only detectably 
enriched in one sample, failing to enrich above a raw enrichment score of 2 in any 
sample, or with fewer than 5 barcodes associated, were penalized to avoid over-weighting 
of low-enrichment samples. The final BASEHIT score was defined as the square-root of 
the sum of the squares of the corrected z-score and the raw enrichment score, and 
therefore reflects both the degree to which a protein was enriched by a particular 
microbe, the internal replicates based on different barcodes associated with that protein, 




On-yeast binding confirmations. Individual proteins were recloned into the backbone 
yeast-display vector as described for library construction, except no randomized barcode 
fragment was included. Individual sequence-verified clones were transformed into 
chemically competent yeast cells prepared with the Frozen-EZ Yeast Transformation II 
Kit (Zymo Research) and grown in SDO-Ura. Yeast were induced for 24 hours in SGO-
Ura and adequate surface display was confirmed by staining with 1:1000 anti-FLAG PE 
antibody (BioLegend). Yeast cells (0.1 OD) were pelleted and resuspended in 100 µL 
PBE. 10 µL of biotinylated bacteria prepared as described for screening were added, and 
the yeast were incubated with shaking for 1 hour at 4°. The yeast were washed once with 
100 µL PBE, resuspended in 100 µL PBE with 1:200 Streptavidin-PE (BioLegend), and 
incubated with shaking for 30 minutes at 4°. The yeast were washed once with 100 µL 
PBE, resuspended in 200 µL PBE, and analyzed on a Sony SA3800 spectral analyzer 
(Sony Biotechnology). Binding to yeast displaying particular proteins was compared to 
binding of yeast transformed with the empty yeast display vector. 
 
Protein purification. Protein ectodomains were cloned into pCER243, a derivative of 
pD2610-v2 (ATUM Bio). Protein ectodomains were cloned in-frame with an upstream 
H7 leader sequence and downstream 3x(GGGGS) linker and hIgG1 Fc fragment with an 
N297A mutation to abolish all effector functions. Expi293 cells (Thermo Fisher) were 
transfected with the expression plasmids using ExpiFectamine 293 Transfection Kit by 
manufacturer protocols (Thermo Fischer). Proteins were purified from clarified media 4 
days post-transfection using magnetic Protein A beads (Lytic Solutions). Proteins were 
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eluted with 100 mM glycine pH 3.0, and immediately neutralized with 1M Tris pH 8.0 
and buffer exchanged into PBS. Protein purity was verified by SDS-PAGE. Protein 
concentration was measured by absorbance at 280 nm. Proteins were snap-frozen in 
liquid nitrogen and stored at -80°C until use. 
 
Bacterial flow cytometry. Bacteria from saturated cultures (0.5-10 µL of culture volume) 
were pelleted and resuspended in 50 µL PBE with recombinant protein (0.05-5 µM final 
concentration of staining protein), and incubated with shaking for 1 hour at 4°C. Bacteria 
were washed twice with 200 µL PBE, resuspended in 50 µL PBE with 1:100 anti-hIgG-
PE secondary antibody (BioLegend), and incubated with shaking for 30 minutes at 4°C. 
Bacteria were washed once with 200 µL PBE, resuspended in 200 µL PBE, and analyzed 
on a Sony SA3800 spectral analyzer (Sony Biotechnology). Binding of Fc-fusion proteins 
was compared to binding of Fc alone. IL18BP was prepared as described previously, and 
staining was identical except 1:100 anti-His-PE secondary antibody (BioLegend) was 
used to detect protein binding. 
 
Bacterial whole-cell ELISA. 1 OD of saturated bacterial culture was pelleted and washed 
three times with PBS pH 7.0. The bacteria were resuspended in 1 mL PBS pH 7.0, and 1-
10 µL of bacterial cell suspension was added to a flat-bottom Nunc MaxiSorp plate 
(Thermo Scientific) and brought to a total volume of 100 µL in PBS pH 7.0. The plate 
was sealed and incubated with shaking overnight at 4°. Pre-coated plates were washed 
once with 250 µL wash buffer (PBS pH 7.0 with 0.05% Tween 20) and blocked with 
shaking for three hours at room temperature in 150 µL blocking buffer (PBS with 1% w/v 
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BSA). Blocked plates were washed three times with 100 µL wash buffer. Protein (0.01-
20 µg/mL final concentration of staining protein) was added in 100 µL total volume in 
blocking buffer, and plates were incubated with shaking for two hours at room 
temperature. Stained plates were washed three times with 100 µL wash buffer, and 100 
µL of blocking buffer with 1:5000 goat anti-human IgG HRP (Millipore Sigma) was 
added. Plates were incubated with shaking for 1 hour at room temperature. Plates were 
washed three times with 100 µL wash buffer. 50 µL TMB substrate (BD Biosciences) 
was added to the wells and plates were incubated for 15 minutes in the dark at room 
temperature. 50 µL 2N sulfuric acid was added to the wells and absorbance at 450 nm 
was measured in a Synergy HTX Multi-Mode Microplate Reader (BioTek). 
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Fig. 4.1. BASEHIT identifies host-microbe interactions. (A) BASEHIT profiling enables 
screening of hundreds of isolates representing a broad sample of the human microbiome 
against the human exoproteome. BASEHIT results identify global patterns as well as 
highlight individual bacterial activities. (B) Validation of the BASEHIT method using a 
gold-standard host-microbe interaction. GFP labeled yeast displayed human IgG1-Fc 
enriched following selection with biotinylated S. aureus cells. (C) and (D) Test selection 
with the E. coli isolate strain MS21-1 prominently identifies binding to CD55 and 
CEACAM1, the targets of the pathogenic Dr-family adhesin present in the MS21-1 






Fig. 4.2. Identification of thousands of novel interactions between host proteins and 
resident microbes. (A) Screening and validation pipeline to assess global breadth of host-
microbe interactions. (B) Heatmap visualization of all possible binary interactions 
between 477 screened strains and 2688 host proteins. (C) and (D) Orthogonal validations 
of newly identified host-microbe interactions by flow cytometry (C) or ELISA (D). 
Staining with indicated Fc-fusion proteins (red) is compared to Fc-control protein (black). 
  
 146 
Fig. 4.3. Host-microbe interaction patterns vary substantially across the collective human 
microbiome. (A) tSNE dimensional reduction of all BASEHIT scores for all strains, 
colored by phylum. (B) Four strains with variable levels of interaction are highlighted, 

















Fig. 4.4. Host-specific interactions vary across closely related strains of microbes. (A) 
Bar plot of interactions with skin-expressed proteins across Staphylococcus isolates. Each 
shaded region encompasses strains of individual species. Each column represents a single 
strain, and the dotted line indicates the score cutoff of 5. (B) FAT2 staining of two S. 
warneri isolates with different BASEHIT scores validates the strain variability in protein 
binding. (C) Interactions of Fusobacterium strains isolated from multiple tissues with 
immune proteins. The size and color of the circle indicates the score bin (<1, 1-5, or >5) 
for each indicated strain to the individual proteins. (D) R. gnavus strain NWP327 binding 
to all screened proteins. Proteins highly expressed on T cells are highlighted in blue, and 
mucus-associated trefoil factors TFF1 and TFF2 are highlighted in pink. (E) Staining of 
R. gnavus strains NWP327 (red), 325 (blue), and 326 (black) show strain-level variability 
in CD7 binding. (F) Staining of R. gnavus NWP327 with increasing concentrations of 












Chapter 5: A human secretome library screen reveals a role for Peptidoglycan 
Recognition Protein 1 in Lyme borreliosis 
 
This chapter contains text that was first published essentially in this form in: 
Gupta A, Arora G, Rosen CE, Kloos Z, Cao Y, Cerny J, Sajid A, Hoornstra D, 
Golovchenko M, Rudenko N, Munderloh U, Hovius JW, Booth CJ, Jacobs-Wagner C, 
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Lyme disease, the most common vector-borne illness in North America, is caused 
by the spirochete Borrelia burgdorferi. Infection begins in the skin following a tick bite 
and can spread to the hearts, joints, nervous system, and other organs. Diverse host 
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responses influence the level of B. burgdorferi infection in mice and humans. Using a 
systems biology approach, we examined potential molecular interactions between human 
extracellular and secreted proteins and B. burgdorferi. A yeast display library expressing 
1031 human extracellular proteins was probed against 36 isolates of B. burgdorferi sensu 
lato. We found that human Peptidoglycan Recognition Protein 1 (PGLYRP1) interacted 
with the vast majority of B. burgdorferi isolates. In subsequent experiments, we 
demonstrated that recombinant PGLYRP1 interacts with purified B. burgdorferi 
peptidoglycan and exhibits borreliacidal activity, suggesting that vertebrate hosts may use 
PGLYRP1 to identify B. burgdorferi. We examined B. burgdorferi infection in mice 
lacking PGLYRP1 and observed an increased spirochete burden in the heart and joints, 
along with splenomegaly. Mice lacking PGLYRP1 also showed signs of immune 
dysregulation, including lower serum IgG levels and higher levels of IFNγ, CXCL9, and 
CXCL10.Taken together, our findings suggest that PGLYRP1 plays a role in the host’s 
response to B. burgdorferi and further demonstrate the utility of expansive yeast display 




 Lyme disease is the most common tick-borne illness in North America. The 
causative spirochete Borrelia burgdorferi is primarily transmitted by Ixodes scapularis 
ticks [1]. The disease in humans often begins with a pathognomonic skin rash, erythema 
migrans. Disseminated infection can lead to arthritis, carditis, and neurological 
symptoms, among other clinical manifestations [2, 3]. 
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 The pathogenesis of Lyme disease is multifactorial, involving both bacterial 
components that influence virulence, dissemination and infectivity, and host factors that 
are responsible for inflammation and the modulation of infection [4, 5]. The success of B. 
burgdorferi as a pathogen can be attributed, in part, to its morphology. Its outer 
membrane contains lipid raft-like microdomains that are associated with lipoproteins [6]. 
Some of the surface displayed lipoproteins are immunogenic and are involved in the 
pathogenesis of Lyme disease. To evade host defenses and to interact with specific host 
factors, B. burgdorferi alters the expression of various lipoproteins throughout its life 
cycle [7, 8]. In addition, flagellin helps maintain the corkscrew-like shape of the 
spirochete and facilitate movement [9]. B. burgdorferi also possesses an atypical 
peptidoglycan (PG) in which the canonical lysine or meso-diaminopimelic acid residue at 
the third position of stem peptides is replaced by ornithine [10, 11]. The PG meshwork 
surrounds the cytoplasmic membrane and is composed of glycan strands cross-linked by 
short peptides containing D- and L-amino acids [12]. In diderm bacteria, including B. 
burgdorferi, the outer membrane shields the PG meshwork from the external 
environment [13]. PG, including that of B. burgdorferi [11], can be recognized by host 
pattern recognition receptors and stimulate immune responses [14]. The mammalian 
immune response to B. burgdorferi involves both humoral and cell-mediated factors that 
help to control or eliminate spirochetes [15-17]. There is a critical need to identify 
specific host immune proteins that interact with spirochete components, including 
lipoproteins, flagellar proteins, peptidoglycan and glycolipids. 
Traditional approaches to identify potential interactions between host immune 
proteins and B. burgdorferi ligands are slow and arduous, requiring overexpression of 
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bacterial ligands and potential immune receptors in their native forms. It is imperative to 
develop new methods of characterizing immune interactions with the spirochete in a 
high-throughput manner. Systems biology approaches, such as yeast display technology, 
enable simultaneous screening of large numbers of candidate host proteins. Yeast display, 
in particular, enables facile expression of mammalian host proteins in their native 
conformations at high surface densities that allow detection of even low-affinity 
interactions [18]. In this study, we employed a recently developed technology termed 
BASEHIT (BActerial Selection to Elucidate Host-microbe Interactions in high 
Throughput) to simultaneously and comprehensively assess potential molecular-level 
interactions between B. burgdorferi and thousands of human extracellular and secreted 
proteins. Through this screen, we identify Peptidoglycan Recognition Protein 1 
(PGLYRP1) as a key host protein that binds the atypical peptidoglycan of B. burgdorferi 




Identification of human host factors that interact with B. burgdorferi 
 We used a recently developed combinatorial screening technology termed 
BASEHIT to identify specific human proteins that interact with B. burgdorferi and thus 
may be involved in pathogenesis or protection. The principle of the BASEHIT assay 
entails using intact, surface-biotinylated B. burgdorferi to pan a curated, genetically-
barcoded yeast-display library of >1,000 human extracellular and secreted proteins. Yeast 
clones expressing bacterial-binding proteins are isolated by magnetic separation using 
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streptavidin microbeads and are identified by next-generation sequencing of their specific 
barcode sequences (Figure 5.1A). Because the expression of B. burgdorferi virulence 
factors can vary with temperature, we performed BASEHIT with cultures grown at either 
33°C or 37°C. Out of the more than 1000 proteins present in the library, only human 
peptidoglycan recognition protein 1 (PGLYRP1) exceeded a stringent significance 
threshold at both temperatures (Figure 5.1B). We expanded our screen to encompass a 
wider range of Borrelia species and strains, again grown at both 33°C and 37°C, 
including isolates from diverse geographic origins (Table S1). We observed that bacteria 
from the genus Borrelia showed significantly greater binding to PGLYRP1 as compared 
to hundreds of phylogenetically diverse non-Borrelia species (Figure 5.1C). PGLYRP1 
was also found to bind to a small number of Gram-positive strains with scores above 3 
only, but overall PGLYRP1 binding to Borrelia was stronger as compared to most Gram-
positive bacteria (Supplementary file S1 available on the PLOS Pathogens website). B. 
burgdorferi N40 also exhibited additional predicted interactions with select human 
extracellular and secreted proteins (Table S2). 
 
PGLYRP1 binds and kills B. burgdorferi 
 To determine whether PGLYRP1 directly binds to B. burgdorferi N40, a 
prototypic isolate commonly used in many laboratories, interaction studies were carried 
out using sandwich ELISA. We observed a robust, dose-dependent interaction between 
recombinant Fc-tagged human PGLYRP1 (0-100 ng) and whole cell B. burgdorferi lysate 
(Figure 5.2A). A weak non-specific binding was observed with Fc domain alone, which 
did not increase with concentration. 
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 To further validate the potential interaction between PGLYRP1 and B. 
burgdorferi, we performed flow cytometry based binding assays. Since PGLYRP1 is 
conserved in humans and mice with 67% identity (Figure S1), we tested whether mouse 
PGLYRP1 also recognizes B. burgdorferi. Both murine and human PGLYRP1 bound to a 
majority of B. burgdorferi cells at two different concentrations (10 and 40 µg/ml), while 
secondary antibody alone showed weak reactivity to spirochetes. As a control, we used 
recombinant CD55-His8 (40 µg/ml), a host immune protein that was predicted by the 
yeast display screen to be unable to bind B. burgdorferi (Figure 5.1). As shown in Figures 
5.2B and 5.2C, purified murine or human CD55-His8 did not recognize B. burgdorferi. 
We also observed concentration-dependent binding of human and mouse PGLYRP1 to B. 
burgdorferi (Figure S2), while secondary antibody alone showed only weak binding. 
Collectively, these results confirmed the interaction between B. burgdorferi and both 
human and murine PGLYRP1.  
 PGLYRP1 is known to be a bactericidal protein expressed by the myeloid cells, 
primarily neutrophils [19, 20]. B. burgdorferi was incubated with purified human 
PGLYRP1 for 48 hours in microaerophilic conditions at 33°C. The borreliacidal activity 
of PGLYRP1 was assessed by BacTiter-Glo Microbial Cell Viability Assay, which has 
been performed routinely for live Borrelia estimation [21-25]. We found that the purified 
human PGLYRP1 shows borreliacidal activity in a concentration-dependent manner, as 
shown in Figure S3. These results suggest that human PGLYRP1 can bind and kill 
Borrelia in vitro. 
 
Neutrophil mediated phagocytosis and killing of Borrelia  
 155 
 Neutrophils kill bacteria in a variety of ways which include the release of granules 
that contain many microbicidal enzymes [26]. We compared the neutrophils isolated from 
mouse bone marrow of BALB/c wild type to BALB/c mice that lack an intact pglyrp1 
gene (WT and PGLYRP1-/-). Neutrophils were incubated with fluorescent-dye (eFluor 
670)-labeled B. burgdorferi at different ratios. The percent of neutrophils that 
phagocytosed fluorescent Borrelia were analyzed by flow cytometry. Our data shows that 
PGLYRP1 deficiency does not affect the ability of neutrophils to phagocytose B. 
burgdorferi (Figure S4). 
 Further, the neutrophil mediated Borrelia killing assay showed that there was no 
significant difference in the borreliacidal activity of neutrophils derived from BALB/c 
WT and PGLYRP1 knockout mice (Figure S5). Based on our data, it is apparent that the 
absence of PGLYRP1 does not affect the ability of neutrophils to kill Borrelia in vitro.  
 
PGLYRP1 binds to B. burgdorferi peptidoglycan 
 PGLYRP1 has been shown to have a ligand-binding groove that is specific for 
peptidoglycan [20]. We, therefore, confirmed the binding of PGLYRP1 with B. 
burgdorferi PG. As shown in Figure 5.3A, a dose-dependent interaction was observed by 
ELISA between purified PG and hPGLYRP1. Furthermore, flow cytometry-based 
binding assays revealed that the binding between B. burgdorferi and human/murine 
PGLYRP1-His8 was reduced with the addition of B. burgdorferi PG, indicating the 
specificity of this interaction (Figures 5.3B and 5.3C).  
 
PGLYRP1 influences murine Lyme borreliosis  
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 To assess the role of PGLYRP1 in the pathogenesis of Lyme borreliosis, we 
compared the outcomes of B. burgdorferi infection of BALB/c WT and PGLYRP1-/- 
mice. BALB/c mice can readily be infected with spirochetes, and while they do not 
develop severe tenosynovitis like C3H mice, they are useful for the study of murine B. 
burgdorferi infection [27]. The BALB/c WT and PGLYRP1-/- mice were infected with 
1x106 spirochetes injected subcutaneously. Spirochete burdens in the heart and joint 
tissues were assessed at 25 days post infection (dpi), and skin burdens were assessed by 
ear punch biopsies at 14 and 25 dpi. There was no difference between the WT and 
PGLYRP1-/- mice in the skin burden at either 14 or 25 dpi (Figures 5.4A and 5.4B). 
However, the PGLYRP1-/- mice had a significantly higher spirochete burden in the hearts 
and joints at 25 dpi (Figures 5.4C and 5.4D), suggesting a role for PGLYRP1 in 
controlling B. burgdorferi dissemination during the systemic phase of infection. 
Furthermore, B. burgdorferi infection induced modest splenomegaly in PGLYRP1-/- mice 
compared to WT animals, which may represent activation and expansion of splenic 
immune cells due to higher B. burgdorferi burden (Figure 5.4E). 
 Histopathological evaluation was performed to examine the development of acute 
tenosynovitis in the mice. The ankle (tibiotarsal) joints from WT and PGLYRP1-/- mice 
(N =3 uninfected controls per genotype and 25 infected mice per genotype) were 
examined and assessed for the presence and severity of inflammation. Of the 6 uninfected 
control mice tibiotarsal joints, only 1 joint (WT tibiotarsal) had trace inflammation (score 
of 0.5). However, in the 50 tibiotarsal joints examined at 25 dpi, 44% of the tibiotarsal 
joints from WT and 28% tibiotarsal joints from PGLYRP1-/- mice developed an 
inflammatory response. Since BALB/c mice do not develop the frequency and severity of 
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tenosynovitis found in C3H mice, we did not find any differences in tenosynovitis 
severity of tibiotarsi (Figure 5.5A). These results suggest that, while the lack of pglyrp1 
led to higher B. burgdorferi burden in animals, joint inflammation was not significantly 
different. 
 The hearts from the 6 uninfected control and 50 infected mice 25 dpi described 
above were examined for the presence and severity of inflammation [28, 29]. None of the 
uninfected control mice were positive for carditis. However, in 50 mice examined at 25 
dpi, 84% of the WT and 60% of PGLYRP1-/- infected mice demonstrated inflammation 
in the heart. There were no significant differences in cardiac severity scores between the 
groups (Figure 5.5B). Taken together with the tenosynovitis scores, these data 
demonstrate that lack of pglryp1 does not significantly impact the severity of 
inflammation of hearts and joints in BALB/c mice infected with B. burgdorferi. 
 To determine the effect of PGLYRP1 deletion on the B. burgdorferi specific 
antibodies, we measured antibody responses to spirochete antigens via sandwich ELISA. 
There was a significant reduction in B. burgdorferi-specific IgG in the sera obtained from 
PGLYRP1-/- mice compared to WT BALB/c mice, collected at 25 dpi (Figure 5.6A), 
while no differences were observed in B. burgdorferi-specific IgM levels at 25 dpi 
(Figure S6).To determine the role of PGLYRP1 on class switching and concomitantly 
antibody effector functions, we assessed B. burgdorferi specific IgG1, IgG2a, IgG2b and 
IgG3 antibodies levels by ELISA. Similar to the overall IgG responses, the levels of B. 
burgdorferi-specific IgG1, IgG2a, IgG2b and IgG3 were significantly lower in 
PGLYRP1-/- infected mice than in WT BALB/c after 25 dpi (Figures 5.6B-E). 
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 Furthermore, serum cytokine profiles were assessed in both WT and PGLYRP1-/- 
mice 25 dpi, using a mouse cytokine/chemokine array panel. Sera from uninfected WT 
and PGLYRP1-/- mice were also probed as baseline controls. Increase in pro-
inflammatory cytokines IFN-γ (Figure 5.7A), and related cytokines CXCL-9 (Figure 
5.7B), CXCL-10 (Figure 5.7C) was observed in infected PGLYRP1-/- mice as compared 
to parent WT BALB/c mice. The PGLYRP1-/- mice did not show significant differences 
in other cytokine levels, including TNF-α, IL-10, IL-4, IL-5, IL-10, IL-17, CXCL-1, 
MCP-1, MIP-1B, and MIP-2 levels compared to infected WT BALB/c mice (Figure S7). 
These results show that the pglyrp1 absence in the mice increased the Th1 cytokine 




 The pathogenesis of Lyme borreliosis is multifactorial and is associated with the 
virulence of the pathogen and the host response to B. burgdorferi. This complex interplay 
can influence the outcome of the infection and result in varying disease phenotypes [6]. 
Unbiased combinatorial approaches, such as BASEHIT, present an unparalleled 
opportunity to identify key host factors that interact with B. burgdorferi. In this study, we 
probed 53 different Borrelia isolates against 1,031 extracellular human proteins. 
PGLYRP1 was identified as the most prominent candidate that interacts with multiple B. 
burgdorferi isolates grown at 33°C and 37°C.  
It has been reported that there are temperature-related changes in Borrelia gene 
expression, which has been shown by different groups [30-32]; Several antigenic 
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lipoproteins present on the Borrelia surface have been shown to be induced at 37°C, such 
as OspC, BbK2.10, ElpA1, Erp proteins and P21 [30-34]. In BASEHIT, we found that 
the PGLYRP1 interaction with Borrelia enhanced marginally at 37°C compared to 33°C. 
This suggests that temperature-dependent changes in virulence-related gene expression in 
Borrelia may enhance PGLYRP1 binding and may allow us to differentiate between 
interactions happening at different stages of the spirochete life cycle. 
PGLYRP1 is an innate recognition protein that binds to PG. Among the many 
spirochete components that contribute to pathogenesis, it has recently been shown that B. 
burgdorferi sheds PG during growth, and this activity may be associated with 
inflammation during infection [11]. Using BASEHIT, we found that PGLYRP1 binds 
more efficiently to B. burgdorferi spp., as compared to the other bacteria tested. This may 
be due to the distinct morphology of B. burgdorferi or the unusual chemical composition 
of PG [11, 35]. 
In line with this interpretation, we demonstrated direct binding of B. burgdorferi 
to PGLYRP1, which could be reduced by supplementation with excess PG. This finding 
intrigued us since B. burgdorferi is a diderm bacteria with an outer membrane and a layer 
of peptidoglycan in the periplasmic space [36]. Peptidoglycan recognition proteins 
(PGRPs) have been shown to directly bind to peptidoglycan in the bacterial cell wall in 
Gram-positive bacteria [37]. In our screen, PGLYRP1 did recognize a small number of 
Gram-positive bacteria. However, it is unclear why all of the Gram-positive bacteria 
screened were not recognized. There may also be variation in peptidoglycan and 
peptidoglycan-associated proteins across the Gram-positive bacteria used in this screen.  
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We think PGLYRP1 can bind to exposed peptidoglycan present on dividing 
Borrelia as well as to damaged spirochete. Spirochetes also have unique peptidoglycan 
which is continuously shedded and some of the shedded peptidoglycan may be loosely 
associated with other antigens (Figure 5.8) [11]. The stronger binding of PGLYRP1 to 
Borrelia could also be due to the unique ornithine within borrelial PG [11]. BASEHIT 
screen indicates that PGLYRP1 may have a binding preference for unusually modified 
peptidoglycan in Borrelia. It is also possible that PGLYRP1 may differentially recognize 
cell-surface peptidoglycan (due to cross-linking with associated molecules in the cell 
wall, etc), compared to free/soluble peptidoglycan, which is why PGLYRP1 only 
interacted with a small number of Gram-positive bacterial strains while failed to bind 
many Gram-positive strains tested. For Gram-negative bacteria, PGRPs have been shown 
to bind uniformly with the outer membrane, which covers the thin layer of peptidoglycan 
and is composed of lipopolysaccharide (LPS) [38]. In addition to PG, PGRPs bind LPS 
and other components of the outer membrane using additional binding sites outside of the 
peptidoglycan-binding groove [37, 39-44]. The ability of PGLYRP1 to bind B. 
burgdorferi may be completely mediated by PG or involve additional lipoproteins on the 
outer membrane, given the structural similarity to Gram-negative bacteria [45]. 
Variations in the surface lipoproteome may account for differences in efficiency scores 
for PGLYRP1 interaction with the multiple Borrelia isolates in BASEHIT. These data 
indicate that the PGLYRP1 may also bind to additional ligands present on the Borrelia 
surface.  
PGLYRP1 is involved in antimicrobial response and has been shown to kill 
bacteria by inducing oxidative, thiol, and metal stress [46]. In Gram-positive bacteria, 
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PGRPs have direct interaction with PG, which allows for bacterial killing [38, 41]. 
PGRPs are able to induce a stress response in Gram-negative organisms by binding to the 
outer membrane and activating a two-component system that involves a transmembrane 
sensor and cytoplasmic regulator, leading to bacterial death [44, 47]. Our experiments 
show that PGLYRP1 had direct bactericidal activity against Borrelia. The role of 
PGLYRP1 in B. burgdorferi pathogenesis and dissemination is further corroborated by 
higher load of B. burgdorferi in hearts and joints of mice lacking PGLYRP1. The 
enhanced spirochete load in these tissues further substantiates our in vitro data that 
PGLYRP1 can directly kill Borrelia. The alteration in immunoglobulin responses against 
B. burgdorferi, observed in PGLYRP1-/- mice also suggests a role for this protein in 
adaptive immune responses. This may also be partially responsible for higher heart and 
joint burden, as antibody responses help combat B. burgdorferi infection [48, 49].  
B. burgdorferi exhibits a tropism for heart and joint tissues during murine 
infection, which are the main sites of inflammation. In many cases, an increase in the B. 
burgdorferi burden in mice is associated with increased severity of disease [50, 51]. In 
our study, PGLYRP1 deficiency in BALB/c mice did not result in differences in carditis 
and tenosynovitis severity, despite a higher pathogen load. This finding is consistent with 
some studies where disease severity and spirochete numbers do not necessarily correlate 
[51, 52]. Further studies in different strains of inbred mice including animals that develop 
both severe and mild tenosynovitis, as well as experiments involving different doses and 
isolates of B. burgdorferi will be needed to fully elucidate the influence of PGLRYP1 on 
Borrelia pathogenesis. 
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PGLYRP1 has been shown to modulate inflammation in multiple murine models 
for experimental colitis, asthma, and contact dermatitis [19, 53, 54]. In addition, 
PGLYRP1 can complex with bacterial PG as a ligand for TREM-1 (Trigger receptor 
expressed on myeloid cells), a pro-inflammatory receptor implicated in innate immune 
activation [55]. In our study, PGLYRP1-/- mice exhibited a differential cytokine profile 
with notable increases in serum IFN-y, CXCL-9, and CXCL-10 levels, favoring a Th1 
immune response. The downstream effects of these elevated pro-inflammatory markers 
remain unclear, as it may be a consequence of higher pathogen burden or directly related 
to the absence of PGLYRP1. These studies suggest an immunomodulatory role of 
PGLYRP1; however, further work is warranted to understand these mechanisms in Lyme 
disease pathogenesis. 
 In conclusion, we identified novel human immune proteins that bind B. 
burgdorferi through an unbiased systems proteomics screen (BASEHIT). Our results 
show that BASEHIT may be very selective and only identified a small number of 
immunogenic proteins that could potentially interact with Borrelia. However, it is 
possible that Borrelia adhesins may not be accessible enough to be detected or their 
expression level is too low for the Borrelia isolates used in the assay  
To our knowledge, this novel method is the only approach to screen a large 
number of pathogens and identity interacting partners from a library of more than 1000 
human secretory proteins in a simple and efficient manner and will provide a new 
benchmark in identifying host-pathogen interactions against Borrelia. In particular, we 
uncovered a novel interaction between PGLYRP1 and B. burgdorferi. We confirmed this 
interaction using orthogonal methods and identified a role for PGLYRP1 in controlling B. 
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burgdorferi burden during murine infection. This revealed a new aspect of B. 
burgdorferi- host interactions, where PGLYRP1 binds to Borrelia cells and kills the 
rapidly dividing spirochete. B. burgdorferi, in turn, may be able to subvert this attack by 
shedding muropeptides that neutralize PGLYRP1 during dissemination to other tissues. 
PGLYRP1 not only controls Borrelia growth through direct interactions, but also 
indirectly by enhancing effective antibody responses. The role of PGLYRP1 in the 
humoral response could be due to its involvement in inflammatory signaling and 
maintaining a balance between Th1/Th2 responses, which may also affect pathogenesis. 
Further applications of BASEHIT may enable the identification of additional host factors 
involved in pathogenic processes caused by Borrelia and other bacterial species.  
 
MATERIALS AND METHODS 
 
Ethics Statement: All experiments performed in this study were conducted in 
accordance with the Guide for the Care and Use of Laboratory Animals. Protocols were 
approved by the Institutional Animal Care and Use Committee at Yale University 
(Protocol Permit Number: 07941). All efforts were made to reduce animal suffering 
during this study. 
 
Borrelia culture: For screening, 53 isolates of several Borrelia species were grown at 
33°C and 37°C in Barbour-Stoenner-Kelly H (BSK-H) complete medium (Sigma-
Aldrich, #B8291) with 6% rabbit serum. The live cell density was ~106-107 cells/mL as 
determined by dark field microscopy and hemocytometric analysis. The species included 
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various isolates of relapsing fever spirochetes and Borrelia burgdorferi sensu lato 
complex, such as, B. miyamotoi, B. anserina, B. crocidurae, B. duttonii, B. hispanica, B. 
persica, B. burgdorferi sensu stricto, B. mayonii, B. carolinensis, B. americana, B. 
kurtenbachii, and B. afzelii (S1 Table). Spirochetes were washed twice with PBS, 
resuspended in PBS containing 5 µM Sulfo-NHS-LC-Biotin (BioVision, #2326-50), 
incubated at 37°C for 30 min, washed again with PBS, and glycerol stocks (10% v/v in 
PBS) were made for future use in yeast display screening assays. A low passage (P<5) 
clonal isolate of B. burgdorferi N40 grown at 33°C in complete BSK-H medium was 
used throughout the study. 
 
Yeast library screening: Details of library construction and selections are described in 
Chapters 3 and 4, although the precise composition of the yeast library and scoring 
system are variations on those previously described. Briefly, a library of barcoded 
plasmids containing the extracellular portions of 1031 human proteins was expressed in 
Saccharomyces cerevisiae strain JAR300 and maintained in SDO-Ura (Synthetic drop-
out media, US Biological #D9535 prepared with 20 g/L glucose, according to 
manufacturer's instructions). Expression of surface protein display was induced by 
culturing the library in media containing 90% galactose and 10% glucose for 24 hours at 
30°C. 1x107 Induced yeast cells were harvested in a sterile 96-well v-bottom microtiter 
plate. Yeast cells were resuspended in 100 µL PBE (PBS + 0.5% w/v BSA + 0.5 mM 
EDTA) with 10 µL of biotinylated bacteria added and incubated for 1 hour at 4°C with 
shaking. Yeast cells were washed once with 200 µL PBE, resuspended in 100 µL PBE 
containing 1 µL of streptavidin microparticles (Spherotech, 0.29 µm, #SVM-025-5H) and 
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incubated for 1 hour at 4°C with shaking. Yeast were washed once with 200 µL PBE and 
bead bound cells were selected by magnetic separation and subsequently expanded in 1 
mL SDO-Ura supplemented with chloramphenicol at 30°C. DNA was extracted from 
selected yeast cell libraries using Zymoprep-96 Yeast cell Plasmid Miniprep kits or 
Zymoprep Yeast cell Plasmid Miniprep II kits (Zymo Research) according to standard 
manufacturer protocols. DNA was amplified with custom primers and sequenced using 
an Illumina MiSeq and Illumina v2 MiSeq Reagent Kits according to standard 
manufacturer protocols. Barcode counts were extracted from raw NGS data using Python. 
 All enrichment calculations were performed using edgeR [56]. The score for each 
gene is defined as the overall enrichment for that gene (relative to the unselected library) 
multiplied by the percentage of barcodes associated with the gene that enriched (defined 
as logFC >0). Since a negative log fold change means a protein was depleted, so for 
simplicity, all negative values are set to zero.  
 
Enzyme-linked immunosorbent assay (ELISA) for analysis of B. burgdorferi 
interaction with human PGLYRP1: Spirochetes were grown to the density of ~107 
cells/mL and harvested at 5000 x g for 15 minutes. Cells were washed twice with PBST 
(PBS containing 0.05% Tween-20), pelleted and lysed using Bug-buster Protein 
Extraction Reagent (Novagen, #70921-3), as previously described [57]. Protein 
concentration in the lysate was measured by absorbance at 280 nm. In a 96-well plate, 
wells were coated with 100ng of B. burgdorferi lysate. Samples were blocked with 1% 
BSA followed by incubation with either recombinant human PGLYRP1 conjugated with 
an Fc tag or a control protein fused with an Fc tag at varying concentrations (1 ng-100 
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ng) for 1 hour at 37°C. After washing and incubating with Goat anti-human IgG HRP 
conjugated secondary antibody (Sigma-Aldrich, #AP309P) (1:5000), KPL Sureblue TMB 
Microwell Peroxidase substrate, 1-component (Seracare, #5120-0077) was added. The 
reaction was stopped with 2 M sulfuric acid, and absorbance was read at 450 nm. 
 
Human PGLYRP1 binding to B. burgdorferi PG: PG was purified as previously 
described [10, 11, 58]. Then, 96-well flat-bottom microplates were coated overnight at 
room temperature with poly-L-lysine solution (0.1% w/v). Wells were washed twice with 
PBST and 100 µL of intact PG sacculi (1µg/mL in PBS) isolated from B. burgdorferi 
B31 MI was added to duplicate wells, with PBS alone as a negative control. After 
overnight incubation at 4°C, wells were washed twice with PBST and blocked with PBS 
containing 3% BSA. After washing, recombinant human PGLYRP1 (R&D Systems, 
#2590-PGB) was added to each well at a concentration of 500 ng/mL in PBS containing 
1% BSA. After incubating for 2 hours at 30°C, wells were washed with PBST and 100 
µL 6X-His Tag polyclonal antibody, HRP (Invitrogen, #MA1-135-A488) was added at 
1:20,000 dilution. Plates were incubated for 1 hour at room temperature with shaking, 
followed by washing with PBST and adding 1-Step Ultra TMB-ELISA Substrate 
Solution (Seracare, #52-00-03). After allowing color development to proceed for 10 
minutes, reactions were stopped by addition of 2 M sulfuric acid and the absorbance was 
measured at 450 nm. 
 
Borreliacidal assay: The BacTiter Glo microbial cell viability assay provides a method 
for determining the number of viable microbial cells in culture based on quantitation of 
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the ATP present by measuring luminescence. The luminescent signal is proportional to 
the amount of ATP present, which is directly proportional to the number of viable cells in 
culture [21-25]. To test the borreliacidal activity of human PGLYRP1-His8 (0-66.7 
ng/µl), we incubated the protein with 1x105 spirochetes in microaerophilic conditions at 
33°C for 48 h in a final volume of 300 μL, and calculated the percent viable spirochetes 
using BacTiter-Glo (Promega) as described previously [21-25]. 
 
Flow cytometry based PGLYRP1 and PG binding assay: Low passage B. burgdorferi 
were cultured to a density of ~106-107 cells/mL, washed two times with PBS and 
incubated with either recombinant human PGLYRP1 (with 8X-His tag), recombinant 
mouse PGLYRP1 (with 6X-His tag) (Sino Biological, #50115-M08H), recombinant 
human CD55 (with 8X-His tag), or murine CD55 (with 8X-His tag) at room temperature 
for 1 hour. Varying concentrations of purified B. burgdorferi PG [11] were used for this 
assay. PG preparation had been sonicated prior to use and consisted of fragmented 
sacculi. Borrelia PG was pre-incubated with either murine or human PGLYRP1 and was 
subsequently added to Borrelia to test for binding. After a co-incubation period of 1 hour, 
spirochetes were fixed in 4% PFA, washed three times with PBS and blocked in 1% BSA 
overnight at 4°C. The spirochetes were probed anti 6X-His monoclonal antibody- 
conjugated to Alexa Fluor 488 (ThermoFisher, #MA1-21315-488) and run through 
SA3800 Spectral Analyzer (Sony Biotechnology). The data was analyzed by FlowJo. 
 
In vivo infection of mice: Pathogen-free BALB/c mice wild-type (WT) (Jackson 
Laboratory) and BALB/c: Pglyrp1tm1Rdz/Pglyrp1tm1Rdz (PGLYRP1-/-) knockout mice [53, 
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59], 6 to 8 weeks of age were infected with low passage B. burgdorferi (1x106 
spirochetes subcutaneously, 7-9 mice/group). Uninfected WT and PGLYRP1-/- BALB/c 
mice were used as controls. Ear punches were taken at 14- and 25-days post-infection to 
compare the Borrelia burden in the skin. At 25 days post infection (dpi), heart and joint 
tissue punches were also collected to quantify the spirochete levels. The spleen weights 
were measured to assess splenomegaly. The protocol for the use of mice was reviewed 
and approved by the Yale Animal Care and Use Committee. 
 
Phagocytosis assay: Bone marrow cells from BALB/c WT and PGLYRP1-/- mice were 
harvested and neutrophils were separated using density gradient centrifugation [60]. B. 
burgdorferi were labeled with eBioscience Cell Proliferation Dye eFluor 670 
(ThermoFisher, #65-0840-85 which binds to any cellular protein containing primary 
amines, and the spirochetes were washed multiple times to remove excess dye. 
Neutrophils were kept in RPMI1640 culture medium, supplemented with 10% (vol/vol) 
fetal bovine serum. Neutrophils and spirochetes were mixed in different ratios from 1:1 to 
1:30. The suspensions were incubated for 60 minutes at 37°C in the presence of 5% CO2 
in 96-well U-bottom plate. After incubation, the suspensions were centrifuged at 500x g 
for 10 min. The pellets were washed twice with PBS, fixed in 2% PFA, and kept at 4°C 
until further processing. The cells were run through LSRII flow cytometer and analyzed 
by FlowJo software. Neutrophils were gated based on forward and side scatter, and 
Borrelia phagocytosing cells were identified by fluorescence detected with a 660/20 band 




Neutrophil killing assay: Bone marrow cells from BALB/c WT and PGLYRP1-/- mice 
were harvested and neutrophils were separated using density gradient centrifugation [60]. 
Neutrophils were kept in DMEM culture medium, supplemented with 10% (vol/vol) fetal 
bovine serum. Neutrophils and B. burgdorferi (1X105) were mixed in the ratio of 1:1 in 
the absence or the presence of mouse serum (10%). The suspensions were incubated for 
60 minutes at 37°C in the presence of 5% CO2 in a 96-well flat-bottom plate in 50 µL. 
After incubation, 250 µL BSK-H media was added to the suspensions and kept at 33°C 
for 72 hours. The Borrelia numbers were counted in Neubauer chamber under the 
microscope. The experiment was performed three times in triplicates. 
 
Quantification of Borrelia burden: DNA was extracted from heart, joint, and ear punch 
samples using Qiagen DNeasy Blood & Tissue Kit, Qiagen. Quantitative PCR was 
performed using iQ-SYBR Green Supermix (Bio-Rad). For quantitative detection of B. 
burgdorferi burden within mouse tissue samples, q-PCR was performed with DNA using 
flagellin (flaB), a marker gene for Borrelia detection. The mouse β-actin gene was used 
to normalize the amount of DNA in each sample. The nucleotide sequences of various 
primers used in specific PCR applications are indicated in Table S3. 
 
Antibody titers against B. burgdorferi: IgG and IgM titers against B. burgdorferi were 
detected in mouse sera by ELISA, as described above. Briefly, wells were coated with 
lysate of B. burgdorferi, blocked, and incubated with mouse sera diluted in 1% BSA at 
varying titers (1:200, 1:2000, 1:20,000, 1:200,000). After washing, Goat anti-mouse IgM 
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HRP conjugated antibody (1:10,000, ThermoFisher #62-6840) or Rabbit anti-mouse IgG 
HRP conjugated antibody (1:10,000, ThermoFisher, #61-6520) or Goat anti-mouse 
IgG1/IgG2a/IgG2b/IgG3 HRP (1:10,000, Abcam, ab97240, ab97241, ab97250, ab97260) 
antibody was added. KPL Sureblue TMB Microwell Peroxidase substrate, 1-component 
was added, and the reaction was stopped with 2 M sulfuric acid. The absorbance of wells 
was read at 450 nm.  
 
Cytokine profile: Serum collected from each group of mice was sent for cytokine 
analysis by the Mouse Cytokine/Chemokine Array 31-plex (MD-31) performed by Eve 
Technologies. The cytokines represented by this array are Eotaxin, G-CSF, GM-CSF, 
IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 
(p70), IL-13, IL-15, IL-17A, IP-10, KC, LIF, LIX, MCP-1, M-CSF, MIG, MIP-1α, MIP-
1β, MIP-2, RANTES, TNFα, and VEGF. 
 
Heart and joint histopathology analysis: Mice were euthanized by CO2 asphyxiation 
and the heart and one rear leg from each mouse were immersion-fixed in 10% neutral 
buffered formalin (NBF) (hearts) and Bouin’s (Ricca Chemical Corp.) or 10% solution 
NBF followed by Decal Solution (rear leg). Hearts were bisected and then tissues were 
processed, embedded, sectioned and stained with hematoxylin and eosin (HE) by routine 
methods (Comparative Pathology Research Core in the Department of Comparative 
Medicine, Yale School of Medicine). The tibiotarsi were scored in a blinded fashion for 
tenosynovitis severity using the 3 point Barthold scoring system: 0 (negative), 1 
(minimal), 2 (moderate), to 3 (severe), by an experienced veterinarian (CJB) (trained in 
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veterinary pathology, as previously described [29, 61]. The hearts were also scored in a 
blinded fashion for carditis severity on the Booth 5 point scale system of 0 (negative), 1 
(minimal), 2 (mild), 3 (moderate), 4 (marked) to 5 (severe), as previously described [29]. 
 
Gene cloning and expression: Human PGLYRP1 (amino acids 22-196) or CD55 
(human amino acids 35-353 or mouse amino acids 35-362) was cloned into pEZT-Dlux, a 
modified pEZT-BM vector. Modifications included insertion of an H7 Leader Sequence 
followed by an AviTag (Avidity), HRV 3C site, protein C epitope, and an 8X His tag. 
Modified pEZT-BM vector was a kind gift from Ryan Hibbs (Addgene plasmid #74099). 
Expi293 cells (ThermoFisher, #A14527) were transfected with the PGLYRP1 or CD55 
expression plasmid using ExpiFectamine 293 Transfection Kit (ThermoFisher, # 
A14524). Protein was purified from clarified media by nickel-nitrilotriacetic acid 
chromatography and desalted into PBS. For Fc-tagged proteins, human PGLYRP1 
(amino acids 22-196) was cloned into pD2610-v1 (ATUM Bio) as an N-terminal fusion 
to the Fc fragment of human IgG1, with an N297A mutation to eliminate all effector 
functions, and a 3X (GGGGS) linker sequence. Expi293 cells (Thermo Fisher) were 
transfected with the PGLYRP1 or control Fc expression plasmid (containing the Fc 
fragment and linker sequence) using ExpiFectamine 293 Transfection Kit (Thermo 
Fisher). Protein was purified from the supernatant 96 hours post-transfection using 
Protein A sepharose (Gold Biotechnology). The column was washed with PBS and eluted 
using 100 mM glycine pH 3.0. Eluted protein was immediately neutralized with 1 M Tris 
pH 8.0 and desalted into PBS. Protein purity was verified by SDS-PAGE. Protein 
concentration was measured by absorbance at 280 nm. 
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Statistical analysis: The analysis of all data was performed by Student’s t-test, Mann-
Whitney, or ANOVA in Prism 8.0 software (GraphPad Software, Inc., San Diego, CA). 
A p-value of <0.05 was considered statistically significant. 
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Figure 5.1. Screening with Yeast-display library. (A) Schematic of yeast-display 
screen- A library of yeast cells, each displaying a single human protein encoded by a 
uniquely bar-coded plasmid was pooled and mixed with surface biotinylated Borrelia. 
The BASEHIT library was scaled to 96-well magnetic separation format for this screen. 
Magnetic separation using streptavidin microbeads, followed by next-generation 
sequencing was used to identify yeast displaying proteins that bind to the bacterial cells. 
Plasmid DNA was isolated and sequenced to identify the proteins (B) Host Interactions 
with B. burgdorferi N40- spirochete from the cultures grown at 33°C or 37°C were 
surface biotinylated and used for yeast selections, as described above. The data shows 
average scores of four independent runs of the selection on the 33°C grown sample and 
one run on the 37°C grown sample. The scores were normalized for diverse microbes (i.e. 
Escherichia coli, Staphylococcus aureus, Bacillus subtilis, Shigella flexneri, and 
Bifidobacterium adolescentis) as background correction for non-specific binding activity. 
(C) PGLYRP1 interaction with Borrelia species- Samples from 53 Borrelia isolates, 
grown at two different temperatures (when possible), were screened against the host 
protein library as described above for B. burgdorferi, as were 370 additional bacterial 
samples. The score for each gene is defined as the overall enrichment for that gene 
(relative to the unselected library) multiplied by the percentage of barcodes associated 
with the gene that enriched (defined as logFC >0). The calculated scores of Borrelia 
species were compared with those of the other bacteria. The bars represent mean ± SD 
and p-values reflect a Mann-Whitney U-te
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Figure 5.2. Binding of PGLYRP1 with B. burgdorferi. (A) ELISA results show the 
interaction of human PGLYRP1 with lysate of B. burgdorferi. The lysate was 
immobilized on microtiter wells and probed with increasing concentrations of either 
recombinant human PGLYRP1-Fc protein (1-100 ng, red bars) or Fc control protein 
(gray bars). The values plotted represent the mean ± SEM of three replicates from a 
single experiment. p-value is displayed in the graph and reflects a student t-test. (B and 
C) Binding of human (B) and mouse (C) PGLYRP1 to B. burgdorferi. The culture was 
grown to a density of 106 CFU/mL and incubated with varying concentrations of 
recombinant PGLYRP1-His8 (10 µg/mL in green, 40 µg/ml in red). B. burgdorferi bound 
to recombinant PGLYRP1-His8 was measured using a secondary AF488-His6 monoclonal 
antibody by flow cytometry. Overlay histograms show protein binding to B. burgdorferi 
identified by Alexa Fluor 488, His6 monoclonal antibody. Binding of recombinant 
human/murine CD55-His8 (40 µg/ml in blue) to B. burgdorferi was used as control. The 
background binding of AF488-His6 alone with B. burgdorferi is shown in gray shaded 
region. Results from one independent experiment are shown here. For (B) and (C), the Y-

































Figure 5.3. PGLYRP1 shows competitive binding to purified peptidoglycan and B. 
burgdorferi. (A) ELISA shows the binding of recombinant human PGLYRP1 at two 
concentrations, 100 and500 ng/ml to peptidoglycan (PG) sacculi isolated from B. 
burgdorferi (Bb) as compared to a PBS negative control. The values plotted represent the 
mean ± SEM of two technical replicates from a single experiment. (B and C) Flow 
cytometry-based experiment showing binding of human (B) and mouse (C) PGLYRP1 to 
B. burgdorferi, after pre-incubating the protein in the absence (red) and presence (blue) 
of B. burgdorferi PG. Recombinant PGLYRP1-His6 (1 µg/mL) was pre-incubated with 
Borrelia PG (10 µg/mL) and then added to live B. burgdorferi overlay histograms show 
PGLYRP1 binding to B. burgdorferi identified by Alexa Fluor 488, His6 monoclonal 
antibody. Results from one independent experiment are shown here. For (B) and (C), the 
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Figure 5.4. Comparison of Borrelia burden in WT BALB/c and PGLYRP1-/- 
knockout mice. Wild-type BALB/c and PGLYRP1-/- mice (at least n=7 in each group) 
were infected with 1x106 spirochetes by subcutaneous injection. (A and B) Skin B. 
burgdorferi burden was assessed by ear punch biopsies at 14 d (A) and 25 d (B) post 
infection, by qPCR for Borrelia specific gene (flaB) normalized to mouse β-actin. (C and 
D) B. burgdorferi burden was assessed in hearts (C) and joints (D) at day 25, by qPCR as 
above. Results from two independent experiments are shown. Each data point represents 
the value of an individual animal. (E) The extent of splenomegaly was expressed as 
spleen weights in WT and PGLYRP1-/- mice infected with B. burgdorferi at day 25. 
Results from one independent experiment are shown here. Each data point represents the 










































































Figure 5.5. Comparison of tenosynovitis and carditis severity after infection between 
WT BALB/c and PGLYRP1-/- knockout mice. (A) Histopathology scores from 
tibiotarsi for individual mice in infected wild-type mice (WT Inf) and infected 
PGLYRP1-/- mice (PGLYRP1-/- Inf) at 25 days post infection. Tibiotarsi were scored by 
blinded examination for tenosynovitis on a scale of 0 (negative) to 3 (severe). (B) The 
severity of cardiac inflammation in the heart of infected WT and PGLYRP1-/- mice 25 d 
post infection. Hearts were scored in a blinded fashion for carditis on a scale of 0 
(negative) to 5 (severe). Similar to tenosynovitis scores, PGLYRP1-/- infected mice 
demonstrated no significant difference in carditis scores compared to WT mice. Results 
from at least two independent experiments (at least n=7 in each group) are pooled and 



































































































































































































Figure 5.6. Difference in antibody level after B. burgdorferi infection in mice. 
Antibody levels in uninfected wild type BALB/c (WT) and PGLYRP1-/- mice were 
compared with those in the infected ones (at least n=7 in each group). Representative 
results from one independent experiment are shown. (A) Whole cell lysate of B. 
burgdorferi was coated on microtiter plate and serum from either uninfected WT, 
infected WT, uninfected PGLYRP1-/- or infected PGLYRP1-/- mice was used at varying 
dilutions. The binding was measured by secondary goat anti-mouse IgG HRP-conjugated 
antibody. Statistically significant increase in binding was observed at IgG titers 1:200, 
1:2000, 1:20000 in infected WT compared to infected knockout mice. (B-E) Levels of 
different IgG isotypes (IgG1, B; IgG2a, C; IgG2b, D; IgG3, E) were measured against B. 
burgdorferi lysate, using mouse serum at varying dilutions. The binding was measured by 
secondary goat anti-mouse IgG1, IgG2a, IgG2b or IgG3 HRP-conjugated antibody. 
Statistically significant increase was observed in IgG1, IgG2a, IgG3, and IgG2b at 1:200 
and 1:2000 dilution in infected WT compared to infected PGLYRP1-/- mice. 
Representative results from one independent experiment are shown. Each data point 
represents an individual animal in the corresponding group. The bars represent mean ± 







Figure 5.7. Differential cytokine profile after infection with B. burgdorferi in mice. 
Serum cytokine profile was assessed in both wild-type and PGLYRP1-/- mice 25 d post-
infection ((at least n=7 in each group) using a mouse cytokine/chemokine 31-plex (MD-
31) array. An increase in pro-inflammatory cytokines IFN-γ (A) and related cytokines- 
CXCL-9 (B) and CXCL-10 (C) was observed in infected PGLYRP1-/- mice as compared 
to parent BALB/c mice. Representative results from one independent experiment are 
shown. Each data point represents an individual animal in the corresponding group. The 
































































































Figure 5.8: Schematic showing Borrelia membrane architecture and PGLYRP1 
binding. B. burgdorferi is a diderm bacteria where the outer membrane surrounds the 
peptidoglycan layer and protects it from the external environment. The peptidoglycan 
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Figure S1. Multiple sequence alignment of human and mouse PGLYRP1. 
 
Figure S2. Concentration-dependent binding of human PGLYRP1 to B. burgdorferi. 
Spirochetes from B. burgdorferi culture were incubated with increasing concentrations of (A) 
recombinant human PGLYRP1-His8, and (B) recombinant mouse PGLYRP1-His6, at 
concentrations 0.01 µg/mL, 0.1 µg/mL and 1 µg/ml. Representative results from one 
independent experiment are shown. Each data point represents an individual animal in the 
corresponding group. Data is expressed as the percentage of spirochetes that were shown to 
bind. The Y-axis represents relative cell counts calculated as percentage of the maximum 
events (Borrelia). 
 
Figure S3. PGLYRP1 dependent killing of B. burgdorferi. Human PGLYRP1- His8  (0-66.7 
ng/µl) was incubated with B. burgdorferi (1x105) for 48 hours in 96-well plate, keeping final 
volume 300 µl. The viability was assessed by BacTiter Glo assay. The graph shows effect of 
human PGLYRP1 concentration on Borrelia (BbN40). Results from one independent experiment 
performed in triplicates are shown here. 
 
 Figure S4. In vitro phagocytosis assay using neutrophils from wild type (WT) and 
PGLYRP1-/- mice. The neutrophils isolated from mouse bone marrow were incubated with 
eFluor 670 dye-labeled B. burgdorferi at different ratios for 1 hour. The neutrophils were 






phagocytosed Borrelia. High and low represent the ratio of 30 and 1 (B. burgdorferi, 1x105). Y-
axis represents relative cell counts calculated as percentage of the maximum events (Borrelia). 
(B) The graph show percent of phagocytic neutrophils plotted against Borrelia numbers. Results 
from three independent experiments are shown. The bars represent mean ± SEM and p-values 
reflect Student t-test. 
 
Figure S5. Comparison of Borrelia killing using neutrophils from WT and PGLYRP1-/- 
mice: Neutrophils isolated from mouse bone marrow were incubated with 1x105 B. burgdorferi 
for 1 hour in DMEM media in the absence (A) or presence of 10% mouse serum (B). The assay 
was performed in 96-well flat-bottom plates and volume was 50 µl. After 1 hour, 250 µl of BSK-
H medium was added to the wells. The plates were incubated in microaerophilic conditions at 
33°C for 72 hours. The Borrelia numbers were counted in Neubauer chamber under the dark-
field microscope. The Y-axis represents B. burgdorferi numbers (in 2.5 x 106). The experiment 
was performed in triplicates and results from one independent experiment are shown. The bars 
represent mean ± SEM and p-values reflect the Mann-Whitney test. 
 
Figure S6. B. burgdorferi specific IgM titers in mice. Antibody levels in uninfected wild type 
BALB/c (WT) and PGLYRP1-/- mice were compared with those in the infected ones (at least n=7 
in each group). A representative result from one independent experiment is shown. Whole-cell 
lysate of B. burgdorferi was coated on a microtiter plate and serum from either uninfected WT, 
infected WT, uninfected PGLYRP1-/- or infected PGLYRP1-/- mice was used at 1:200 dilution. 
The binding was measured by the secondary Goat anti-mouse IgM HRP-conjugated antibody. 
No significant difference in IgM level was observed in infected WT compared to infected 
PGLYRP1 knockout mice. Each data point represents an individual animal in the corresponding 







Figure S7. Cytokine response in WT and PGLYRP1-/- mice. The infected PGLYRP1-/- mice 
also showed overall different levels (in pg/mL) of CXCL-1, MCP-1, MIP-1B, and MIP-2 (A) and 
TNF-α, IL-10, IL-4, IL-5, IL-10, IL-17 (B) as compared to BALB/c mice infected mice although 
the profiles were statistically insignificant. Representative results from one independent 
experiment are shown. Each data point represents an individual animal in the corresponding 


























Table S1. Borrelia species & number of corresponding isolates screened. 
Species  Number of Isolates Screened 
Borrelia burgdorferi sensu lato complex 39 
B. afzelii 13 
B. Americana 1 
B. burgdorferi sensu stricto 9 
B. carolinensis 3 
B. garinii 3 
B. kurtenbachii 1 
B. mayonii 1 
Borrelia sp. 8 
 
Relapsing fever spirochetes 17 
B. anserina 1 
B. crocidurae 1 
B. duttonii 1 
B. hispanica 1 
B. miyamotoi 12 
B. persica 1 
 
Table S2. Top hits from yeast display screen for B. burgdorferi N40 in order of descending 
enrichment scores 
 
Protein Function with Panther family annotation 
B. burgdorferi 






PGLYRP1 peptidoglycan immune receptor activity 4.029706862 2.65251E-05 
LAIR2 
inhibitory receptor present on mononuclear 
leukocytes 
2.49646777 0.015449324 
LRRTM2 synapse organization 1.512091167 0.292351992 
REG4 




vascular endothelial growth factor-activated 
receptor activity 
0.924634238 0.292351992 
TYRO3 tyrosine-protein kinase receptor pthr24416 0.796971217 0.292351992 
TLR3 




melanocyte protein pmel 17-related 
pthr11861 
0.749663357 0.099486635 
GP1BB glycoprotein ib beta pthr22650 0.679232994 0.292351992 
IL32 
pro-inflammatory cytokine that act on 



















File S1. Excel spreadsheet containing the numerical data for Figure panels Fig 1B and Fig 1C in 
separate sheet tabs; BASEHIT scores for PGLYRP1 and corresponding Borrelia isolate 
(“Borrelia PGLYRP1 Scores”); BASEHIT scores for PGLYRP1 for non-Borrelia isolates (“Non-
borrelia PGLYRP1 Scores”; and list of Borrelia isolates used and corresponding species 











hPGLYRP1   MSRRSMLLAWALPSLLRLGAAQETEDPACCSPIVPRNEWKALASECAQHLSLPLRYVVVS  60
mPGLYRP1   -----MLFACALLALLG--------LATSCSFIVPRSEWRALPSECSSRLGHPVRYVVIS  47
**:* ** :**           :.** ****.**:** ***:.:*. *:****:*
hPGLYRP1   HTAGSSCNTPASCQQQARNVQHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGH  120
mPGLYRP1   HTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGP  107
***** **:* **:********** : ******.********* ********:.* *:*
hPGLYRP1   LWNPMSIGISFMGNYMDRVPTPQAIRAAQGLLACGVAQGALRSNYVLKGHRDVQRTLSPG  180 
mPGLYRP1   IWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPG  167
:********:****:*****: :*:*** .** ***::* ***** :******* *****
hPGLYRP1   NQLYHLIQNWPHYRSP  196






Mouse PGLYRP1 1 µg/ml 0.1 µg/ml 0.01 µg/ml
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